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FOR Ml PAREHTS
There are things that are known and 
things that are unknown; in between 
are doors.
William Blake
Let no man deceive himself* If any 
man among you seemeth to he wise in 
this world, let him become a fool, 
that he may be wise.
Paul
ABSTRACT
An animal model of hyperlactataemia induced by phenformin, an 
orally-active antidiabetic drug, has been developed using streptozo­
tocin-diabetic rats. A comparison of blood metabolite concentrations 
of fed, starved and streptozotocin-diabetic rats showed that the dia­
betic animal most nearly resembled the human maturity-onset diabetic.
It was found that several agents commonly used to anaesthetise small 
animals had profound effects on blood glucose and lactate concentra­
tions, and experiments comparing the effects of phenformin in pento­
barbitone-anaesthetised rats with those in conscious animals showed 
that barbiturate anaesthesia interfered with the metabolic actions of 
phenformin. An intraperitoneal dose of phenformin of 0.5mmol/kg 
caused hypoglycaemic and hyperlactataemic effects of a suitable mag­
nitude in diabetic animals, and the animal model was used to assess 
the pharmacological actions of compounds related to phenformin and 
the ability of compounds, such as dichloroacetate, to prevent the 
hyperlactataemia caused by phenformin.
Sodium dichloroacetaite was found to be an effective orally-active 
hypoglycaemic agent in starved and streptozotocin-diabetic rats, lower­
ing blood concentrations of the gluconeogenic precursors lactate, pyru­
vate and alanine and often increasing blood ketone body concentrations. 
These metabolic actions were probably consequences of activation of 
tissue pyruvate dehydrogenase. The toxicity of dichloroacetate and 
its metabolites means that other, more specific activators of pyruvate 
dehydrogenase are to be preferred for further study.
The results of experiments in which glucose and gluconeogenic 
precursors were given to starved rats were explained by a hypothesis - 
for the mechanism of action of phenformin involving inhibition of 1TADH 
dehydrogenase. Substrates with HAD -linked oxidations could be dis­
criminated from those, like succinate and fatty acids, with FAD- 
linked oxidations, and succinate may be of use in the treatment of 
clinical lacticacidosis caused by biguanide' drugs,. The ability of. 
phenformin to improve the tolerance of rats to an intraperitoneal 
glucose load, with a concomitant increase in blood lactate concen­
tration, indicated that the drug was increasing the rate of anaero­
bic glycolysis, and glucose uptake into jejiinaJL cells; was increased 
by phenformin. Changes in the tissue concentrations of metabolites 
measured after phenformin treatment in vivo did not generally support 
the hypothesis, although elevated 3-hydroxybutyrate concentrations 
implied a decreased liver mitochondrial MJ)+/MJyR ratio.
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CHAPTER 1 
GENERAL INTRODUCTION
1.1 Fhenforrain
1.1.1 Phenformin-associated lacticacidosis in human, diabetics 
Soon after its introduction, in 1957* a-s an oral hypoglycaemic
agent for use in the treatment of maturity-onset diabetes mellitus, 
phenformin (U -phenethylbiguanide) was found to increase the blood 
lactate concentrations of diabetic patients (Walker et al., i960).
A similar effect had already been observed in guinea pigs
H
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(Tyberghein and Williams, 1957)* The first suggestion of an associ­
ation between phenformin therapy and the olinical syndrome of lactic­
acidosis was reported several years later (Tranquada et al., 1963) 
and by the beginning of 1976 there were 150 published cases of phen­
formin-associated lacticacidosis, many of them, fatal,(Cohen and_
Woods, 1976)* The frequency of phenformin-associated lacticacidosis. 
has been estimated to be 0.25-4 cases per 1000 patients annually 
(Pedersen, 1978) and in Sweden 1.8 cases were found per million daily 
doses (Bergman et al., 1978)# During 1976 more than 5° new cases were 
reported (Gale and Tattersall, 1976) and the high incidence of this 
serious condition has led to a re-examination of the use of biguanides 
in the treatment of diabetes, with the use of phenformin being legally 
curtailed in the U.S^., Canada and Eorway (Kolata, 1979)*
It is generally accepted that in the absence of predisposing 
factors lacticacidosis is not an:appreciablel risk. in patients taking 
therapeutic doses of phenformin. Contra-indications to its use include 
renal disease, which reduces the excretion of the drug} hepatic disease,
which results in impaired lactate and phenformin metabolism; and 
cardiovascular disease, which can produce all of these effects 
simultaneously. There is also evidence that genetic polymorphism 
dictates major inter-individual differences in the metabolism of 
phenformin (Shah et al.♦ 1980; Idle and Islam, 1981) with phenformin- 
induced lacticacidosis beihg associated with impaired hydroxylation 
of the marker debrisoquine (Oates et al., 1981)• Other workers, 
however, suggest that impaired hydroxylation of phenformin, as 
reflected by the debrisoquine test, may be only one among several 
factors involved in the development of lacticacidosis during phen­
formin treatment (Wilholm et al., 1981).
In patients with no co-existing disease the increased blood 
lactate concentration seen with phenformin may be unimportant, since 
it rarely exceeds 2mM (Nattrass et al., 19TT)• Detecting the pre­
sence of the predisposing factors before starting biguanide therapy 
may, however, present problems. Also, a proportion of cases of 
lacticacidosis occur when acute disease such as myocardial infarc­
tion or septicaemia complicate treatment of diabetes and for which 
screening for co-existing disease would be of little value (Nattrass 
and Alberti, 1978). Nevertheless, biguanides are of value as an adjunct 
to dietary control in the obese maturity-onset diabetic and in com­
bined therapy with a sulphonylurea, when control of blood glucose is 
unsatisfactory on sulphonylurea therapy alone. In the latter case 
biguanides may be used to delay the introduction of insulin therapy 
or obviate it entirely in unsuitable cases, and many physicians would 
prefer to maintain an option to use a biguanide, if not phenformin 
(Nattrass and Alberti, 1978).
1.1.2 Metabolic effects of phenformin in experimental animals ..
Considering its importance as a drug in the- treatment of maturity-
onset diabetes relatively few studies have been published of the effects 
of phenformin in whole animals, early work having concentrated on its 
actions in in vitro systems such as isolated muscle preparations. 
Virtually all studies carried out in vivo have been confined to measure­
ment of blood glucose and/or lactate concentrations, often at only one 
time-point after administration of phenformin. The rat has been the 
species most commonly used in investigations of the metabolic effects 
of biguanides and summaries of the effects of phenformin on blood 
glucose and blood lactate concentrations in fed, starved and diabetic 
rats form tables 1.1 — 1.3 *
Phenformin appears to have little or no hypoglycaemic activity in 
starved rats - in some studies statistically significant hyperglycaemia 
was evident - although blood lactate concentrations, when they were 
measured, were increased. Similarly, while phenformin consistently 
elevated blood lactate concentrations in fed rats, the blood glucose 
concentrations of the same animals were usually unchanged or affected 
to a lesser degree. In diabetic rats, however, the hypoglycaemic 
effect of phenformin was usually pronounced. The hyperlactataemic 
action was again statistically significant, and the predominant effect 
of phenformin in rats appears to be an interference with lactate meta­
bolism; elevation of the blood lactate concentration may occur without 
frank hypoglycaemia occurring at the same ,time. Diabetic rats seem 
more susceptible to the hypoglycaemic action of phenformin than fed or 
starved animals so that the compound may better be termed antidiabetic 
rather than hypoglycaemic.
Blood pyruvate »ahd alanine concentrations were elevated in fed 
rats following administration of phenformin (El Defrawy and Buckley, 
1971? Assan et al., 1978; Schlienger et al., 1979)* although the in­
creases were small, except in nephrectomised animals. Acute admini-
stration of phenformin lowered the hepatic glycogen contents of fed 
animals (Tyberghein and Williams, 1957? Blickens and Riggi, 1971? SI 
Defrawy and Buckley, 1971) and starved animals (Tyberghein and Williams 
1957? Williams et al., 1957)» although some workers found no change 
in starved animals (Blickens and Riggi, 1971? Lloyd et al., 1975)* 
Muscle glycogen contents were generally unchanged following admini­
stration of phenformin (Tyberghein and Williams, 1975? Blickens and 
Riggi, 1971? SI Defrawy and Buckley, 1971)•
Blood concentrations of 3-hydroxybutyrate and acetoacetate were 
greatly increased following subacute administration of phenformin to 
nephrectomised rats (Assan et al., 1978)* In starved guinea pigs, 
however, blood 3-hydroxybutyrate concentrations were unchanged and 
acetoacetate concentrations slightly decreased after administration 
of phenformin (Haeckel and Haeckel, 1972). Thus the effect of phen­
formin on ketone body metabolism is unclear, since no other measure­
ments of their blood concentrations appear to have been reported.
Phenformin had no clear action on the plasma non-esterified 
fatty acid and cholesterol concentrations of fed and starved rats 
(Muntoni et al., 197^? Prasannan and Augusti, 1973? Dilman et al.,
1978? Tutwiler, 1978)* Ho other measurements of plasma lipids 
following administration of phenformin to experimental animals appear 
to have been reported.
1.1.3 Mechanism of pharmacological action
The mechanism of biochemical action of phenformin is still not 
certain even after many years of investigation, although it is gener­
ally assumed that the hypogl-caemia and hyperlactataemia are closely 
related. It was initially proposed that the fall in blood glucose 
concentration was due to increased peripheral anaerobic glycolysis 
secondary to an inhibition of aerobic cell respiration (Tyberghein
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and Williams, 1975? Steiner and Williams, 1958)* Interference in 
hepatic gluconeogenesis was suspected and it was confirmed in a vari­
ety of in vitro systems that phenformin could indeed inhibit glucone— 
ogenesis from lactate, pyruvate and alanine (Patrick, 1966; Meyer et al. 
1967? Altschuld and Kruger, 1968; Toews et al., 1970? Haeckel and Haec­
kel, 1972? Cook et altt 1973L; Ogata et alM  1974? Lloyd et al., 1975? 
Cook, 1978? Ho and Kelly, 1980). A lack of stimulation of Cori cycle 
activity in diabetics given therapeutic doses of phenformin, despite 
elevation of blood lactate concentrations, suggested an inhibition of 
gluconeogenesis from lactate, although the basal rate of gluconeogenesis 
was not significantly reduced (Searle and Gulli, 1980).
Ho direct effects on enzymes of the gluconeogenic pathway have 
been found (Williams et^al*, 1957? Haeckel and Haeckel, 1972? Cook 
et al., 1973b) and it was thought that inhibition of gluconeogenesis 
might be secondary to inhibition of aerobic respiration, perhaps due to 
a decrease in the supply of ATP (Altschuld and Kruger, 1968) or the dir­
ection of oxaloacetate to malate caused by a decreased mitochondrial 
HAD+/MI)H ratio (Haeckel and Haeckel, 1972). Inhibition by phenformin 
of aerobic respiration apparently occurred at succinate oxidase, 
cytochromec7reductase and cytochrome oxidase (Steiner and Williams, 1958 
Wick et al., 1958), and inhibition of oxidation of intermediates in the 
tricarboxylic acid cycle was also found (Wick et al., 1958? Kruger et 
al., 1960; Ungar et al.. 1960). Virtually all the evidence impli­
cating inhibition of respiration as the underlying mechanism of action 
of biguanides has, however, been derived from studies carried out in 
vitro and the role of inhibition of respiration in the whole animal is 
not clear. Correlation between respiratory inhibition in vitro and 
hypoglycaemic activity in vivo is poor (lavidoff, 1970), the concen­
tration of drug required for inhibition of respiration (0.5-1mM) is
several orders of magnitude greater than those expected in tissues 
after usual therapeutic doses (Davidoff, 1968) and inhibition of 
gluconeogenesis in perfused livers does not always correlate well 
with the fall in ATP concentration (Cook et al., 1973b).
Other mechanisms of hypoglycaemic action have, therefore, been 
proposed for the biguanides, including inhibition of intestinal 
glucose absorption (Kruger et al., 1970? Caspary and Greutzfeldt, 1971? 
Arvanitakis et al., 1973) and inhibition of fatty acid oxidation 
(Montoni, 1970)* Schafer (1976) proposed that alteration of the 
electrostatic surface potentials of biological membranes is the 
underlying mechanism of nearly all the actions of biguanides.
There is some evidence that phenformin increases the secretion of 
glucagon-like immunoreactivity (GLl) from the gastro-intestinal tract. 
This fgut glucagon* appears to be involved in the stimulation of 
insulin secretion from the pancreas after an oral glucose load 
(Unger et al., 1968) but is itself not nearly so potent a glyco­
genolytic and gluconeogenic agent as is pancreatic glucagon (Goldfine 
et al., 1972), although it competes for the same receptor sites on 
the liver (Bataille et, al*, 1973). Thus release of gut GLI would lead 
to hypoglycaemia by reducing the glycogenolytic and gluconeogenic 
effects of qjancreatic GLI in the liver and possibly by stimulating 
some release of insulin. Marked increases in gut GLI, with no change 
in pancreatic glucagon, were apparent after administration of phen­
formin to humans (Czyzyk et al., 1975? Shima et al., 1975) and chickens 
(Langslow et al., 1974)* Some action by phenformin to limit the hepa­
tic gluconeogenic response to glucagon, secondary to changes in the
2+ 2+amount or distribution of mitochondrial Ca and Mg , has also been 
proposed (Davidoff et al•, 1978; Davidoff and Haas, 1979)*
1.2 Dichloroacetate
1.2.1 Historial review
Diisopropylammonium dichloroacetate was first synthesised in 1952, 
following the isolation of pangamic acid (d-gluconodimethylaminoacetate) 
from apricot stones and its marketing as vitamin B,s (Stacpoole, 1969)* 
The diisopropylammonium moiety was considered to he the pharmacologi­
cally active component of .the vitamin 33 lS molecule (Kraushaar et al. , 
1983) and the dichloroacetate derivative was chosen for further investi­
gations. Over the next ten years diisopropylammonium dichloroacetate 
was reported to be of value in the treatment of cardiovascular diseases 
(Guagliano et al., 1960? Martelli et al., 1963; Ruperti et al., 1963) 
and liver disease (Abdullev, 1966). It was also found to be an anta­
gonist of certain inhibitors of respiration, including cyanide (Santi 
et al., 1965).
In 1962 the chance observation that diisopropylammonium dichloro­
acetate caused a reduction in the blood glucose concentration of dia­
betic rats led to its evaluation as a hypoglycaemic agent (Lorini and 
Ciman, 1962). This work, however, was not continued, and it was not 
until 1970 that interest in diisopropylammonium dichloroacetate was 
revived, when it was established that the active hypoglycaemic moiety 
is the dichloroacetate ion rather than the diisopropylammonium ion 
(Stacpoole and Pelts, 1970)* Many studies followed of the metabolic 
effects of dichloroacetate both in isolated organ preparations (Stac­
poole and Berry, 1971, McAllister et al., 1973) and in whole animals 
(Anderson, 1974? Blackshear e_t al., 1974; Eichner ,et al..,. 1974? 
Blackshear et al., 1975a-). It was established'that one mechanism of 
its biochemical action is activation of hepatic and peripheral pyruvate 
•dehydrogenase (Whitehouse and Randle, 1973? Whitehouse et al., 1974), 
leading to decreased blood concentrations of the main gluconeogenic 
percursors lactate, pyruvate and alanine (Blackshear et al., 1974?
Blackshear et al., 1975&)*
Clinical trials of sodium dichloroacetate were conducted in small 
numbers of maturity-onset diabetics (Stacpoole et al,, 1976? Stacpoole 
et al., 1978) "but most interest was shown in its potential as a treat­
ment for lacticacidosis, particularly that produced by the biguanide 
oral hypoglycaemic drugs. Various animal models of biguanide-induced 
lacticacidosis were developed and dichloroacetate was found to prevent 
(Holloway and Alberti, 1975? Loubatieres et al.. 1976a) or reverse (Louba— 
tieres et al., 1976b; Holloway and Alberti, 1977) hyperlactataemia induced 
by phenformin in rats and dogs.
In 1978, however, it was shown that dichloroacetate can be cata- 
bolised to glyoxylate and oxalate by isolated hepatocytes (Demaugre 
et al., 1978; Harris et al., 1978) and then oxalate production was 
shown to occur in whole animals (Crabb and Harris, 1979)* It became 
clear that to avoid nephrotoxicity associated with oxalate further stu­
dies with activators of pyruvate dehydrogenase should use 2-chloropro— 
pionate rather than dichloroacetate, since 2-chloropropionate cannot be 
metabolised to glyoxylate or oxalate. Also, when dichloroacetate was 
used to treat hypercholesterolaemia a polyneuropathy developed in one 
patient (Moore et al., 1979) and toxic effects, including hind-1 imb para­
lysis, became apparent in animal studies (Kata et al., 1981). These find­
ings have apparently led to a moratorium on chronic administration of 
dichloroacetate to patients (Stacpoole et al., 1979)* Recently dichloro— 
acetate has ..proved positive in the Ames test for mutagens (Herbert et al., 
1979? Herbert et al., 1980) and this is causing concern since dichloro­
acetate is the active ingredient of "pangamic acid” or vitamin Bjg "•
This cure-all is so popular'.among American health food’ faddists that the 
amount of dichloroacetate ingested in vitamin 3 JS by the public far 
exceeds that administered to patients in clinical trials of the drug.
1,2.2. Metabolic effexts of dichloroacetate in experimental animals
HYPOGLICAEMIA ADD HYPOLACTATAEMIA
Dichloroacetate, as the diisopropylammonium or the sodium salt, 
lowered the blood glucose concentrations of diabetic animals at doses 
which had no effect on the normally—fed animal (Lorini and Ciman,; 1962; 
Stacpoole and Felts, 197 Q|_. Anders on,. .1974i Siohner; et al., 1974) * „ Sodium 
dichloroacetate was hypoglycaemic in starved animals (Blackshear et al., 
1974; Goodman et al., 1978; Misbin, 1979) and some hypoglycaemic action 
was also apparent in fed animals (Pegorier et. al., .1978? Ribes et al.,
1979? Guest et al., 1980). An early observation that dichloroacetate 
increased the respiratory quotient of diabetic rats but not that of non­
diabetic animals suggested that the compound increased the peripheral 
utilization of glucose when, as in diabetes, it was impaired (Lorini and 
Ciman, 1962). Fatty acid oxidation is accelerated in conditions such as 
diabetes and starvation in which circulating levels of fatty acids are 
high. This leads to increased concentrations of acetyl-coenzyme A and, 
in the tricarboxylic acid cycle, to increased tissue concentrations of 
citrate, an inhibitor of the key glycolytic enzyme phosphofructokinase.
It was proposed that dichloroacetate was acting to suppress fatty acid 
oxidation, thereby reducing citrate levels, reactivating phosphofructo­
kinase and increasing the rate of glycolysis (Stacpoole and Felts, 1971)* 
It was calculated, however, that the glycolytic rate of muscle from 
starved rats was unchanged after incubation with dichloroacetate (Goodman 
et al., 1978), while stimulation of the rate of glucose oxidation to CO2 
caused by perfusion of rat hearts with dichloroacetate was many times 
greater than the stimulation of the glycolytic rate (McAllister et al., 
1973). The same workers, moreover, found that dichloroacetate increased 
rather than decreased tissue concentrations of acetyl-coenzyme A. This 
increase, and a decrease in the tissue concentration of pyruvate, suggested
that dichloroacetate was directly stimulating pyruvate oxidation at 
pyruvate dehydrogenase.
Dichloroacetate lowered the blood lactate, pyruvate and alanine 
concentrations of fed rats and dogs (McAllister et al., 1973, Pegorier 
et al., 1978; Ribes et al., 1979; Guest et al., 1980), starved rats 
(Blackshear et al., 1974? Whitehouse et al., 1974? Goodman et al., 1978) 
and diabetic rats and.dogs (McAllister et al., 1973? Blackshear et al., 
1975a? Ribes et al., 1979)* These decreases are consistent with an 
activation of pyruvate dehydrogenase in the peripheral tissues resul­
ting in enhanced oxidation of pyruvate (and hence of lactate and alanine). 
Thus a primary mechanism of the hypoglycaemic action of dichloroacetate 
appears to be to decrease gluconeogenesis by decreasing the release of 
precursors from the peripheral tissues. Dichloroacetate decreased the 
release of lactate, pyruvate and alanine from the skeletal muscle of fed, 
starved and diabetic animals (Goodman et al., 1976; Goodman et al., 1978) 
and from all the peripheral tissues, after functional hepatectomy, i» 
starved and diabetic rats (Blackshear et al., 1974; Blackshear et al.,
1975a). It activated pyruvate dehydrogenase in several tissues both in 
vivo and in vitro (Whitehouse et al., 1974).
. Pyruvate dehydrogenase exists in animal tissues in dephosphorylated 
(active) and phosphorylated (inactive) forms inter-convertible through the 
pyruvate dehydrogenase kinase and pyruvate dehydrogenase phosphate phos­
phatase reactions (Linn et al., 1969)* Dichloroacetate inhibits the 
kinase reaction, leading to conversion of pyruvate dehydrogenase into 
its active form (Whitehouse and Randle, 1973? Whitehouse et al♦, 1974).
A mechanism of action involving inhibition of gluconeogenesis is 
consistent with the experimental finding that dichloroacetate is much 
more effective as a hypoglycaemic agent in starved and diabetic animals 
than it is in fed animals, since gluconeogenesis is relatively unimpor­
tant in maintaining glycaemia in fed, non-diabetic animals. In starved 
and diabetic rats infused with dichloroacetate there were decreases in 
the hepatic concentrations of most gluconeogenic intermediates, indica­
ting a deficiency of substrate rather than inhibition at a particular 
enzyme (Blackshear 'et al., 1974? Blackshear et al., 1975a) and -further 
evidence that dichloroacetate causes gluconeogenic substrate deficiency 
in the liver (and kidneys) was obtained when an injection of a mixture 
of lactate, pyruvate and alanine into newborn rats reversed the hypo- 
glyceamia caused by dichloroacetate (Pegorier et al., 1978).
Although direct inhibition by dichloroacetate of hepatic and renal 
gluconeogenesis'has been found under certain conditions in vitro (Stac­
poole, 1977? Lacey and Randle, 1978) its importance in causing hypogly- 
caemia in vivo annears to be slight. Indeed, some workers have found 
little or no inhibition of gluconeogenesis in isolated hepatocytes in­
cubated with dichloroacetate (Crabb et al., 1976? Claus and Pilkis, 1977)*
Dichloroacetate does not appear to have a significant effect on 
glycogen metabolism. Muscle and liver glycogen contents were unchanged 
after administration of diisopropylammonium dichloroacetate to diabetic 
rats (Lorini and Ciman, 1962) and there was no change in hepatic glycogen 
in starved rats (Cascio, 1958). Experiments performed in vitro have con- . 
firmed this lack of action — no effect on the rate of glycogenolysis in 
hepatocytes from fed rats (Crabb et al., 1976? Stacpoole, 1977), ao 
effect on glycogen synthesis from lactate or fructose in hepatocytes 
isolated from starved rats (Stacpoole, 1977) and no change in the glycogen 
content of perfused rat hearts (McAllister et al., 1973).
HTPERKETOHAEMIA
Dichloroacetate increased blood acetoacetate and 3-hydroxybutyrate 
concentrations in starved rats (Blackshear et al., 1974? Goodman et al., 
1978? Misbin, 1979) Lut not in diabetic rats (Blackshear et al., 1975a).
The mechanism of the hyperketonaemia is probably decreased uptake of 
3-hydroxybutyrate by the peripheral tissues* The 3-hydroxybutyrate 
concentration of blood from starved and diabetic rats treated with 
dichloroacetate was maintained after functional hepatectomy while blood 
concentrations of control animals fell sharply,, as. did acetoacetate 
concentrations in control and experimental animals (Blackshear et al., 
1974; Blackshear et al*, 1975a)* The inhibition of peripheral ketone 
body uptake coincident with the decrease in blood concentration ob­
served in diabetic rats can only be explained by a fall in hepatic 
production — the animals were ketotic and so had an innately high rate 
of ketogenesis. Incubation with dichloroacetate of skeletal muscle from 
fed rats decreased the uptake of 3—hydroxybutyrate and again uptake of 
acetoacetate was unaffected (Goodman et al,, 1978). Decreased uptake 
was associated with decreased utilization — the oxidation of 3-hydroxy— 
butyrate to carbon dioxide was inhibited by dichloroacetate in in vitro 
studies with rat diaphragm and hearts (McAllister et al., 1973). The 
mechanism of the inhibition of uptake may be a competition for coenzyme 
A between activated pyruvate dehydrogenase and the enzymes of ketone 
body utilization. Also, increased tissue concentrations of acetyl- 
coenzyme A, secondary to increased pyruvate dehydrogenase activity, 
would be expected to inhibit the formation of acetyl-coenzyme A from 
ketone bodies and hence their uptake.
EFFECTS OB' LIPID METABOLISM
Dichloroacetate has profound effects on lipid metabolism, some of 
which may be explained by its activation of pyruvate dehydrogenase.
The results from different workers are, however, sometimes conflicting 
and the precise nature of the effects of dichloroacetate on lipid meta­
bolism is unclear. For example, plasma non-esterified fatty acid con­
centrations increase, decrease or remain the same; after respectively
oral, intravenous and intraperitoneal administration of dichloroace­
tate to starved rats (Blackshear et al., 1974? Goodman et al., 1978; 
Mishin, 1979)* There is similar uncertainty about the effects of 
dichloroacetate on fatty acid synthesis* Large increases in the 
activities of liver glucose-6-phosphate dehydrogenase and malic 
enzyme, which generate HADPH needed for fatty acid synthesis, have 
been reported after the administration of dichloroacetate to diabetic 
and non-diabetic rats (Anderson, 1974) f suggesting that dichloroace­
tate may enhance fatty acid synthesis* This is consistent with acti­
vation of pyruvate dehydrogenase since a product of the reaction, 
acetyl-coenzyme A, is the starting material for fatty acid synthesis*
It has been shown that the activation of pyruvate dehydrogenase and 
the rate of fatty acid synthesis correlate under certain experimental 
conditions (Taylor and Jungas, .1974; Mapes and Harris, 1975) and indeed 
fatty acid synthesis in isolated hepatocytes has been shown to increase 
on their incubation with dichloroacetate under conditions in which 
pyruvate dehydrogenase activity was also increased (Crabb et al., 1978). 
Others, however, have found an inhibition of the conversion of glucose, 
fructose and lactate into fatty acids in the triglyceride of adipose 
tissue isolated from starved rats, as well as an activation of pyru­
vate dehydrogenase (Whitehouse et al., 1974)* Dichloroacetate also 
caused a decrease in fatty acid synthesis in the adipose tissue and 
liver of fed rats (Stansbie * and Sheriff, 1-978), so it seems that diehloro 
acetate can inhibit fatty acid synthesis despite activating pyruvate 
dehydrogenase.
Activation of pyruvate dehydrogenase might be expected to decrease 
fatty acid oxidation by end-product inhibition, and oxidations of 
oleate and palmitate to carbon dioxide were indeed decreased by dich— 
loroacetate in isolated rat diaphragms (Stacpoole and Felts, 1970;
McAllister et al., 19T3)» although oleate oxidation in adipose tissue 
was unchanged (Stacpoole and Felts, 1.970)* Studies- using isolated hepa— 
tocytes have yielded conflicting results, with ,2mM dichloroacetate 
inhibiting oleate oxidation (Crabb et al., 1976) "but 10mM dichloroace­
tate stimulating palmitate oxidation (Misbin, 1979)*
Bo studies of triglyceride breakdown seem to have been made. ‘Tri­
glyceride synthesis from fatty acids was unaffected by dichloroacetate 
in the diaphragm and epididymal fat-pads isolated from diabetic rats 
(Stacpoole and Felts, 1970). and. in hepatocytes from fed rats (Misbin, 1-91 
Plasma triglyceride concentrations are, however, usually greatly reduced 
by dichloroacetate - in diabetic rats (Felts etal,, 1976), starved rats 
(Misbin, 1979) and non-diabetic but not diabetic dogs (Ribes et al., 
1979)* In the absence of decreased triglyceride synthesis in the peri­
pheral tissues and liver this reduction of plasma triglyceride could be 
due to increased clearance of triglyceride by the extrahepatic tissues, 
a decreased availability of fatty acids in the liver for incorporation 
into triglyceride or an impaired release of triglyceride from the liver. 
Here, again, experimental findings are contradictory. /Liver triglycer­
ide concentration was not altered by dichloroacetate in starved rats 
(Blackshear et al., 1974) and in diabetic rats in which large falls in 
plasma triglyceride were apparent (Felts et al., 1976). In diabetic 
rats infused with dichloroacetate, however, large increases in liver 
triglyceride contents were obtained (Blackshear et al., 1975a). Thus 
the mechanism of the hypo£riglyceridaemic action of dichloroacetate 
is unclear.
Dichloroacetate has little effect on plasma cholesterol concen­
trations in animals although an increase, secondary to activation 
of pyruvate dehydrogenase, might have been expected since acetyl- 
coenzyme A is the starting material for cholesterol synthesis. Bo
changes in plasma cholesterol concentration were seen in starved rats 
(Mishin, 1979) or diabetic dogs (Ribes et^  aly,.. 1979.)»: althougfr non-
diabetic dogs given dichloroacetate subacutely showed a decreased
plasma cholesterol level which did not" return-to normal until six 
days after the end of treatment (Ribes et al«, 1979)*
EFFECTS OB AMUJO ACID METABOLISM
Alanine and glutamine are the main amino acids released from the 
skeletal muscles of the rat (Blackshear et al.. 1975^)* When alanine 
formation in hepatectomised rats was decreased following administra­
tion of dichloroacetate, glutamine accumulation was enhanced, pro­
bably due to direction of glutamate along the glutamine synthetase 
pathway (Blackshear et al.t 1974? Blackshear et al., 1975a)* The 
release of the branched-chain amino acids (leucine, isoleucine and 
valine) was increased following incubation of skeletal muscle iso­
lated from starved and diabetic rats with dichloroacetate (Goodman 
et al.. 1978)* This is consistent with a finding in starved rats of 
increased blood concentrations of these animo acids following infusion 
with dichloroacetate (Blackshear et al., 1975"b) and the mechanism 
could be competition for coenzyme A between activated pyruvate dehy­
drogenase and the oxidative enzymes for the branched-chain 2-oxo acids. 
In isolated hepatocytes, however, dichloroacetate stimulated oxidation 
of leucine to carbon dioxide (Crabb and Harris, 1978), not by any action 
on 2-oxoisocaproate dehydrogenase (an enzyme complex very similar to 
pyruvate dehydrogenase) but by providing glyoxylate, an efficient 2-oxo 
acid acceptor for leucine transamination (Harris et al., 1978)•
EFFECTS OB THE PYRUVATE CARRIER
The carrier which transports pyruvate into the mitochondrion has 
a rather broad specificity - although it seems that 2-oxo acids are the 
preferred substrates various halogenated carboxylic acids are also
transported (Halestrap, 1975)* Dichloroacetate is almost entirely 
dependent on the pyruvate carrier for entry into mitochondria and it 
also enhances the exchange of pyruvate from mitochondria. Pyruvate 
transport may be limiting in pyruvate carboxylation by rat liver mito­
chondria and so may be a rate-limiting step in gluconeogenesis under 
certain conditions. Preincubation with dichloroacetate nearly doubled 
the initial rate of pyruvate uptake by rat liver mitochondria (Para- 
dies and Papa, 1976), an effect- which would tend to . increase the rate of 
gluconeogenesis. The enhancement of pyruvate uptake could be due to 
an increased level of intra-mitochondria! counteranions or, more 
likely, to activation of the translocator — the stimulated uptake 
was characterised by a decrease in the of pyruvate for the trans- 
locator, with no change in Vmax. The significance of this action in 
vivo is uncertain, but there seems to be an association between acti­
vation of pyruvate exchange and inhibition of pyruvate dehydrogenase 
kinase (Halestrap, 1975)*
METABOLISM OF DICHLOROACETATE
Dichloroacetate is metabolised to glyoxylate, oxalate and glycine 
in isolated hepatocytes (Harris et al.t 1978). Oxalate is an inhibitor 
of gluconeogenesis (McClure et al., 1971)• The urinary oxalate con­
tents of rats treated with dichloroacetate were much higher than 
those of control animals, indicating conversion of dichloroacetate 
to oxalate in vivo (Crabb and;Harris, 1979)* Metabolism of dichloro­
acetate reverses cyanide poisoning (Santi et al.. 1960) - the glyoxy­
late could lower the effective cyanide concentration by cyanohydrin 
formation (Harris et al., 1978). Similarly, the conversion of glyo­
xylate to glycollate, if it occurs in vivo, may explain the stimulation 
of ethanol oxidation shown by dichloroacetate, by increasing the 
cytosolic HAD^/BADH ratio (Harris and Crabb, 197.8).
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1.2.3 Metabolic effects of dichloroacetate in man
In healthy, overnight-fasted, humans infusions of a small amount 
of sodium dichloroacetate caused similar effects to those seen in 
animals at higher doses : falls in blood glucose, lactate and alanine 
and an increase in blood 3-hydroxybutyrate concentration (Alberti 
et, al., 1978; Moore and Stacpoole, 1978; . Wells et al., 1980). Various 
side-effects were reported, including mild headaches, injection-site 
pain, lethargy and incoordination.
During clinical trials in non-ketotic maturity-onset diabetics 
(Stacpoole et al.? 1978) and in patients with diabetes or hyperlip- 
oproteinaemia or both (Stacpoole et al.» 1978) dichloroacetate re­
duced the hyperglycaemia with concomitant falls in plasma lactate. 
Plasma ketone body concentrations were increased but plasma insulin
and glycerol levels were usually unaffected. Most notable were de­
creases in plasma triglyceride and cholesterol concentrations, the 
fall in cholesterol being a response not usually seen in animals.
In both studies the decreases in triglyceride were primarily in the 
very-low-density lipoprotein fraction and decreases in cholesterol 
were mainly in the low-density lipoprotein fraction. Haematological 
parameters and liver and kidney function tests were unchanged in 
these patients, but several experienced mild sedation. The appear­
ance of more serious side-effects, including polyneuropathy and -
' i ■
potentially - oxalate stone formation, has led to caution in the 
further use of dichloroacetate in humans.
1.3 Dichloroacetate in the prevention and reversal of phenformin — 
associated lacticac^dogjg
The ability of dichloroacetate to interfere with the supply of 
gluconeogenic percursors to the liver by activation of peripheral 
pyruvate dehydrogenase, with resultant decreases in the blood concen­
trations of lactate, pyruvate and alanine, has been used in attempts 
to reverse or prevent hyperlactataemia induced in experimental animals 
by phenformin. These attempts have usually been successful^ although 
often several moles of dichloroacetate are needed for each mole of 
phenformin used. Phenformin-induced hyperlactataemia was prevented 
in fed rats (Guest, 1980), starved rats (Holloway and Alberti, 1975? 
Holloway and Alberti, 1978), starved dogs (Loubatieres et al., 1978a) 
and diabetic rats (Holloway and Alberti, 1975? Kuhnle et al., 1977?
Man and Alberti, 1977) and it was reversed in fed dogs (Loubatieres ' 
et al., 1977? Arieff et al., 1978) and starved dogs (Alberti and Hollo­
way, 1977? Holloway and Alberti, 1977)* Dichloroacetate also prevented 
hyperlactataemia caused by fructose in rats (Johnson and Man, 1975)> ^y 
exercise in dogs (Merrill e^ al., 1980) and by endotoxin in rabbits
(Merrill and Rosolowsky, 1980) and enhanced the ability of rats to 
exercise at near maximal work loads, probably as a consequence of a 
decreased rate of lactate accumulation (Schneider et al.t 1981).
Dichloroacetate has had only limited success in preventing or 
reversing hyperlactataemia induced by biguanide drugs in humans*
In maturity-onset diabetics receiving a combined therapy of dich­
loroacetate and buformin (butylbiguanide) blood lactate concentra­
tions were similar to those in the same patients when receiving 
bpformin alone (Standi et al.* 1977)* When these patients did an 
ergometer test, however, the rise in blood lactate concentration 
was much less with the combined treatment than with buformin alone. 
When large intravenous doses of dichloroacetate were used in attempts 
to reverse severe lacticacidosis induced by biguanides in three 
patients only one survived (irsigler et al., 1979)* It was recom­
mended that dichloroacetate be used only as part of intensive ther­
apy, which should include dialysis in severe cases. Dichloroacetate 
did, however, lower the blood lactate and pyruvate concentrations of 
a young boy with chronic, congenital lacticacidosis (Coude et al*,
1978).
1*4 The objectives of this thesis
Phenformin is an orally-active hypoglycaemic drug of benefit in 
the treatment of maturity-onset diabetes. Its clinical use has been 
curtailed because in some patients it produces lacticacidosis, which 
may be fatal. The present study was made to develop animal models of 
phenformin-induced lacticacidosis and to use them to investigate the 
mechanism of action of phenformin, to determine the hyperlactataemic 
effects of related compounds and to investigate the activity of com­
pounds of potential use in preventing or reversing phenformin-induced 
hyperlactataemia.
Despite many years of investigation the biochemical mechanism of 
hypoglycaemic and hyperlactataemic action of phenformin is uncertain, 
partly because research has concentrated on in vitro systems using 
very high concentrations of the drug. An animal model was used in an 
attempt to elucidate this mechanism in vivo and under metabolic condi­
tions at least resembling those found in the human maturity-onset 
diabetic•
The metabolic effects of sodium dichloroacetate were studied both 
as an antidiabetic agent in its own right and in combination with phen­
formin, when it was thought that it might prevent the hyperlactataemia 
normally associated with the biguanide. A combined therapy of dich­
loroacetate with phenformin could be of value in the treatment of 
maturity-onset diabetes, and the molar ratio of the two drugs needed 
to prevent hyperlactataemia was; estimated in experimental animals.
CHAPTER 2 
DEVELOPMENT OP AN ANIMAL MODEL OP 
PHENPORICEN-INDUCED HYPERLACTATAEMIA
2.1 Introduction
Most of the studies made of the metabolic effects of phenformin 
in experimental animals have been limited to measurements of blood 
lactate and/or glucose concentrations at one time point after the 
administration of the biguanide. Among studies on rats, only Guest 
(1978) made regular determinations of blood lactate and glucose 
concentrations over a long period and using the same animals, although 
Gulbenkian et al• (1973) and Polacek and Ouart (1974) made serial 
measurements of blood glucose concentration (for a summary, see Tables
1.1 - 1.3). It was decided, therefore, to develop an animal model 
of phenformin-induced hyperlactataemia based on that of Guest (1978), 
which consisted of the intraperitoneal administration of the biguanide 
to normally-fed rats anaesthetised with sodium pentobarbitone, blood 
for lactate and glucose assays being obtained from the tail veins.
The rat was considered suitable because the metabolism of phenformin 
in the rat is more like that of man than is the metabolism of phen— 
formin by the guinea pig, the other contender (see Pig. 2.1) and 
because most of the previous work has been done using this species.
The rat also has advantages over other common species of laboratory 
animal in that it is easy to handle and to dose orally, intraperi- 
toneally and intravenously; blood can readily be sampled from the tail 
and the blood volume is large enough to allow repeated sampling.
Three simple animal models can be used to assess the metabolic 
effects of an antidiabetic compound - the normally-fed, the starved
and the diabetic animal. The last two of these were chosen since
/
their metabolic states are likely to be closer to that of the human 
maturity-onset diabetic than is that of the fed rat. A comparison was 
made of the metabolic states of fed, starved and diabetic rats in an 
attempt to confirm this.
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There are various methods of producing experimental diabetes 
in laboratory animals, including pancreatectomy and the injection 
of antibodies to insulin. The commonest is the use of a /3-cytotoxin 
which specifically damages the ^ -cells of the pancreatic islets, 
leaving the acini and the ct-cells intact. Currently the most 
popular ^ 8-cytotoxins are alloxan and streptozotocin. Streptozotocin 
was chosen for this study because it has greater specificity and 
lower general toxicity than alloxan (Hoftiezer and Carpenter, 1973).
It produces a diabetic state with extrapanereatic lesions similar to 
those found in human diabetics (Karunanayake et al.. 1974) but does 
not appear to show the nephrotoxicity associated with alloxan (Junod 
et al.. 1967). Tissue metabolism in non-ketotic human diabetics may 
more closely resemble that found in streptozotocin-diabetic animals 
than that seen in alloxan-diabetic animals (Mansford and Opie, 1968). 
Also, whereas alloxan-diabetic rats usually cannot survive without 
insulin, rats rendered diabetic by administration of streptozotocin 
can be maintained without insulin therapy, indicating subnormal 
release of the hormone. Thus streptozotocin-diabetic rats may resemble 
human maturity-onset diabetics whose insulin secretion is subnormal 
(Kaul et al., 1978).
Streptozotocin can be used to produce diabetic states of various 
severities. Doses as low as 0.09mmo3/^€ produce mild diabetes, 
while higher doses (0.19 - O.26mmo3/kg i.v.) cause a moderately severe , 
diabetic state in rats (Bar-On et al., 1978? Metzger et al.. 1975? 
Wimshnrst and Manchester, 1970)• A dose of streptozotocin of 
0.19mmol/kg i.v. was chosen for this study.
A comparison was made in starved rats of the effects of various 
anaesthetics on the response of blood lactate and glucose concentra­
tions to the administration pf phenformin. Although an anaesthetic
is usually required to minimise stress-related hyperlactataemia 
during blood sampling (Assan et al.. 1978), attempts were made to 
take serial blood samples from unanaesthetised animals, since most 
common anaesthetics have marked effects on carbohydrate metabolism 
(Macdonald and Wann, 1978). In another experiment an inhibitor of 
microsomal drug hydroxylation, SKF 525-A* was administered in an 
attempt to increase the magnitude of the hypoglycaemic and hyper— 
lactataemic effects of phenformin in starved rats.
2.2 Materials and methods .
2.2.1 Chemicals .
Streptozotocin was obtained from Upjohn International Incor­
porated, Kalamazoo, Michigan, U.S.A. and SKF 525-A (^-diethylaminoe- 
thyldiphenylpropylacetate hydrochloride) was obtained from Smith,
Kline and French Laboratories Ltd., Melwyn Garden City, Hertfordshire. 
Sodium pentobarbitone anaesthetic solution (Sagatal) and analytical 
grade diethyl ether were supplied by May and Baker Ltd., Dagenham, 
Essex. Sodium pentobarbitone solution (Hembutal) was also obtained 
from Abbott Laboratories, Queeriborough, Kent. Urethane and chloral 
hydrate anaesthetic solutions were prepared from the reagent grade 
chemicals supplied respectively by Sigma Chemical Co. Ltd., Poole, 
Dorset and British Drug Houses Ltd., Poole, Dorset. Phenformin 
hydrochloride was donated by Sterling-Winthrop Research Laboratories, 
Fawdon, Newcastle. Its purity was demonstrated by thin—layer chroma­
tography on an alumina F25i^  plate using the solvent system ethanol - 
25$ (w/v) ammonia (4s 1, by volume). Only one spot (Rf * 0.8) was 
visualised under UV light (254nm) and it gave a positive colour 
reaction with a spray reagent used to detect guanidine and biguanide 
groupings (sodium nitroprusside-potassium ferricyanide-eodium hydro­
xide, each 10$ (w/v) in water (1:1:1, by volume) diluted with 9 volumes
of 50$(v/v)aqueous ethanol (Morphy and Wick, 1968)). Enzymes, 
cofactors and substrates used for standards in the determinations 
of lactate, pyruvate, alanine, 3-hydroxybutyrate and acetoacetate 
were obtained from Sigma Chemical Co. Ltd. Guaiacum, peroxidase 
and glucose oxidase were supplied by Hughes and Hughes (Enzymes)
Ltd., Romford, Essex. Kits used in the assay of cholesterol, non- 
esterified fatty acids and ATP were supplied by the Boehringer 
Corporation (London) Ltd., Lewes, East Sussex. All other chemicals 
were obtained from Sigma or British Drug Houses and were of the 
highest grade available.
2.2.2 Materials
’Silastic* brand medical-grade tubing (0.51mm I.D. by 0.94mm O.D.) 
was manufactured by Dow-Coming, Reading, Berkshire and supplied by 
Macarthy Surgical, Dagenham, Essex. Alumina P2S’4 thin-layer chroma­
tography plates (type E, 0.25mm) were supplied by E. Merck* Darmstadt, 
W. Germany. Heparinised; tubes were obtained from Seward Laboratory, 
London.
2.2.3 Animals
Adult male Wistar albino rats were used in all experiments. 
Starvation and induction of diabetes
Starved rats were deprived of food for about 24 hours, with water 
being allowed ad libitum. Other rats were rendered diabetic by intra­
venous administration of freshly-prepared 94*nM streptozotocin solution 
in 0.154M saline buffered to pH 4*5 with 0.1M citrate. For injection 
the animal was restrained in a polythene tube so that anaesthesia was 
not required (see Fig. 2.3). The animal was returned to its cage and 
allowed food and water ad libitum until the experiment, performed 
23-26 hours after administration of streptozotocin. The dose of strep­
tozotocin used was 0.19mmol/kg i.v.
Chronic blood sampling in unanaesthetised animals
The procedure was based on that of Steffens (1969) and a diagram 
of the system used is given in Fig. 2.2. Rats were acclimatized to 
sitting in small restraining cages for increasing lengths of time over 
several days. They were then anaesthetised with sodium pentobarbitone, 
the ventral and dorsal neck areas shaved using a small-animal clipper, 
and cannulae of ’Silastic* tubing inserted into their external jugular 
veins. The cannula was brought out through a hole made in the skin of 
the dorsal neck region and connected to a short length of stainless 
steel tubing. This tubing was bent at a right angle so that on 
suturing the incision it became anchorred in the skin, with about 5™^ 
protruding upwards from the neck of the rat. The ventral incision was 
sutured and the open end of the steel tubing was sealed with a plastic 
cap. During the operation the cannula was kept patent by infusion of 
heparinised saline (500units heparin /ml 0.154M saline). The rats 
were allowed to recover from the operation over several days. During 
this period they were acclimatized to sitting in the restraining 
cages and their cannulae were kept patent by infusion of fresh hepari­
nised saline. All of the surgical procedures were performed by a 
colleague at the University of Surrey. To obtain a blood sample the 
animal was placed in its restraining cage, the cannula cap removed and 
blood mixed with heparinised saline was withdrawn into a syringe acting 
through a 3-way tap. The clean blood sample (about 0.3ml) was withdrawn 
into another syringe and the cannula was refilled with heparinised 
saline (100 units heparinf/rnl 0.154& saline) from a reservoir. Care 
was taken to avoid the introduction of air into the cannula, which was 
immediately recapped at the end of the sampling procedure. The rat was 
left undisturbed in its restraining cage between samplings.
Fig. 2.2 . Diagram of system used for chronic sampling of 1)100(1 from the
heart of unanaesthetised rats
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Pig* 2.«3 v- Diagram of system used for chronic sampling of Blood from the tail 
of unanaesthetised rats and for intravenous administration of streptozotocin.
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In another experiment unanaesthetised rats were restrained in 
a clpsed polythene cylinder (see Pig. 2.3) and "blood sampled from the 
tail veins. Between samplings the rats were returned to their cages. 
Anaesthesia
The commercial preparation of sodium pentobarbitone (60mg/ml) was 
given by intraperitoneal injection (/lml/kg body weight) and the first 
blood sample was usually taken about 0.2h later. Other animals were 
anaesthetised with urethane (14 or l8mmol/kg i.p., given as 2.8M or 
4*5M aqueous solutions respectively), the first blood sample being 
taken 1.5h after injection. Ether anaesthesia was achieved by placing 
the rat in a covered bucket containing a cotton wool pad soaked in 
diethyl ether. During blood sampling anaesthesia was maintained by 
placing a wad of cotton wool soaked in ether near the animal’s nose. 
The animal was returned to its cage between samplings. Chloral 
hydrate was administered at a dose of 1.8mmol/kg i.p. as a 0.9M 
solution in 0.154I£ saline. The first blood sample was taken about 
0.2h after injection.
Collection of blood and liver samples
Blood was sampled from the tail by removing the tip using a 
scalpel blade and collecting into a blood pipette the volume required 
for an assay (0.05ml for glucose, 0.1ml for lactate). The blood was 
immediately expelled into the appropriate deproteinising solution and 
the mixture centrifuged. The blood pipettes were rinsed in hepari­
nised saline (1,000 units heparin /ml 0.154^ saline) to clean them 
and prevent clotting of the sample. The first few drops of blood from 
each bleed were discarded since elevated lactate concentrations would 
be expected, due to tissue damage and venous stasis. Blood flow to 
the tail was encouraged by keeping the animal warm under a lamp.
Larger, terminal volumes of blood were collected from the inferior 
vena cava into a syringe and were immediately deproteinised with an 
equal volume of ice-cold 0.7$ perchloric acid* The mixture was 
centrifuged and the supernatant neutralised with 2M potassium hydro­
xide solution, using Universal Indicator to show the endpoint. To 
prepare serum the blood was allowed to clot at room temperature in 
a narrow glass test-tube before centrifugation. After collection of 
the terminal blood sample, a portion of the liver was rapidly removed 
and squeezed between the plates of tongs previously cooled to the 
temperature of liquid nitrogen. The liver sample was stored in 
liquid nitrogen until assayed for glycogen.
2.2.4 - Administration of compounds
Phenformin hydrochloride was dissolved in distilled water for 
oral administration and in 0.154M saline for intraperitoneal admini­
stration. For a dose of 1 x rmmol/kg, the concentration used was 
0.5xmmol/ml. SKF 525-A (70®M in 0.154M saline) was administered 
intraperitoneally at a dose of 0.14mmol/kg, one hour before admin—  
stration of phenformin. For glucose tolerance tests, the glucose 
(12.5M in distilled water, 8.3mmol/kg i.p.) was administered to 
animals anaesthetised with sodium pentobarbitone.
2.2.5 Assay methods 
Glucose and glycogen
Blood glucose was measured using the glucose oxidase method of 
Morley et al.. (1968) modified for a . 0.05ml blood sample. Glycogen 
was measured in homogenates prepared from freeze-clamped livers by 
extraction and acid hydrolysis according to the method of Pfleiderer 
(1963), followed by estimation of the glucose liberated using the 
method of Morley et al., (1968). Further details are given in 4*2.5*
Lactate, pyruvate, alanine. ATP
Blood L-lactate was measured within 24h of collecting the sample 
by the method of Guest (1978) but using a 0.1ml blood sample. The 
blood sample was dispensed into 0.2ml of ice-cold 0.7M perchloric 
acid. After centrigugation, 0.1ml of the supernatant was incubated 
with 0.1ml HAD*" solution (30mM in distilled water), 1.0ml buffer 
(0.4M hydrazine sulphate and 0.5M glycine; pH 9*0) and 0.02ml lactate 
dehydrogenase suspension diluted in distilled water (about 400U/ml) 
for 1h at 25°c. Lithium L-lactate standards (l-6mM) in 2.5bM sul­
phuric acid were processed similarly and the extinction of tests and 
standards was measured at 34Qnm»
The pyruvate concentration in terminal blood samples was measured 
immediately by a modification of the method of Czok and Lamprecht (1974) 
in which a 1ml sample (perchloric acid supernatant brought to pH 3-5 
with 2M potassium hydroxide solution) was mixed with 1*5ml buffer 
(0.5M triethanoflamine containing 5*n& EDTA; pH 7*6) and 0.05ml HADH 
solution (7mM in distilled water). After reading the extinction at 
340nmf the solution was incubated with 0.01ml lactate dehydrogenase 
suspension diluted in distilled water (about 80(Xj/ml) for 1h at 25° C.
A reagent blank with distilled water in place of sample was used to 
correct for the change in extinction due to the addition of enzyme.
The stoichiometry of the reaction was checked on several occasions 
.using sodium pyruvate standard solutions (0.02 - 0.2mM). The blood 
pyruvate concentration was obtained from the equation blood pyruvate 
concentration (mM) *■ x O.41 x F where F, the dilution factor,
was calculated for each sample from values of blood, perchloric acid 
supernatant and neutralised supernatant volumes.
Alanine was measured in the neutralised perchloric acid super­
natant (pH 7-8) using a method based on that of Williamson (1974).
The sample (1ml) was mixed with 0.5ml buffer (40mM Tris, 1M 
hydrazine hydrate, 1.4®M EDTA; pH 10) and 0.04ml aqueous RAD+
(24mM). The extinction was measui*ed at 340*m» 0.01ml alanine 
dehydrogenase suspension diluted in distilled water (74U/ml) added 
and the mixture incubated at 25°C for 1h. The change in extinction 
at 340nm was determined after correction for a reagent blank. The 
stoichiometry of the reaction was checked on several occasions using 
L-alanine standard solutions (0.025 - 0.1mM). The blood alanine 
concentration was obtained from the equation blood alanine concen­
tration (mM) x 0.25 x F where F was the blood dilution factor.
Blood ATP concentration was determined with a kit using the 
method of Bucher (1947)*
3-hydroxybutyrate . acetoacetate
The concentration of 3-^aydroxybutyrate in blood was determined 
using the method of Williamson and Mellanby (1974) • Since blood 
3-hydroxybutyrate concentrations vary considerably according to the 
metabolic state of the animal, it was necessary to vary the ratio of 
sample volume to DAD+ solution volume in the assay mixture to prevent 
the HAD* from being exhausted. An assay mixture comprising 0.05ml 
sample (neutralised perchloric acid supernatant; pH 7-8), 0.4ml buffer 
(70mM Tris , 1M hydrazine hydrate, 2.7mM EDTA; pH 8.5) and 0.05ml HAD+ 
solution (l5mM in distilled water) was found suitable for blood from 
starved rats while for blood from fed and diabetic animals the 
volumes were 1.0ml sample, 0.5ml. buffer and 0.05ml HAD+ solution.
The change in extinction at 340njn was recorded after the addition of 
0.01ml 3-hydroxybutyrate dehydrogenase suspension diluted in distilled 
water (about 3O^-ml) .; - Sodium DL-3-hydroxybutyrate standards (0.1-2mM, 
equivalent to 0.041 — 0.82mM D—3-hydroxybutyrate) were used to cali­
brate the assay. The 3-hydroxybutyrate concentration in small volumes
of blood obtained in serial sampling was estimated using an assay 
mixture of 1 ml buffer, 0.1ml HAD+ solution and 0.1ml of the unused 
perchloric acid supernatant remaining from the lactate assay. The 
change in extinction at 340nm was measured after incubation for 1h 
at 25°C with 3-hydroxybutyrate dehydrogenase.
Acetoacetate was measured in blood by the method of Mellanby and 
Williamson (1974)• Perchloric acid supernatant neutralised to pH
7-8 (1.0ml) was mixed with 0.5ml buffer (0.1111 potassium dihydrogen 
phosphate - dipotassium hydrogen phosphate; pH 6.8) and 0.05ml HADH 
solution (7mM in distilled water). The change in extinction at 340nm 
was recorded after addition of 0.01ml 3-hydroxybutyrate dehydrogenase 
(about 30 u/ml). The stoichiometry of the reaction was checked on 
several occasions using lithium acetoacetate standards (0.01 - 0.1mM 
in distilled water) and the blood acetoacetate concentration was 
obtained from the equation blood acetoacetate concentration (mM) ■ 
A B 3^ d x 0.25 * F, where F was the blood dilution factor.
Serum lipids
Cholesterol and non-esterified fatty acids were measured in serum 
using assay kits. The method for cholesterol was based on that of 
Roschlau (1974) in which the enzymic production of formaldehyde; from 
cholesterol and its esters was determined colorimetrically. The 
colorimetric determination of non-esterified fatty acids was based on . 
the method of Duncombe (1964)•
Analysis of data;
The statistical significance of differences found in group mean 
blood metabolite concentrations was assessed using Student's t—test. 
Where a variance—ratio test (F—test) indicated that the variances of 
the groups were statistically unequal, a modified form of the t-test 
(the d-test) was used (Bailey, 1959) •
In the figures points or bars represent the group mean with the 
standard error of the mean being shown by vertical lines. In groups 
containing only two observations the points represent the individual 
values and the mean value is not shown.
2.3 Results.
2.3.1, Studies in f-ed and starved.rats .~
The lactate concentrations in blood obtained from unanaesthetised 
fed rats were high (>3.2mM) compared with the value of 1mM usually 
accepted as normal (Table 2.1).
Phenformin (0.375 and 0.50mmol/kg i.p.) did not have marked 
hypoglycaeoic or hyperlactataemic effects in starved, pentobarbitone- 
anaesthetised rats (Fig. 2.4). Although mean blood glucose concen­
trations had fallen sharply at 2h, by 35$ and 30$ respectively, 
decreases of similar magnitude (24$ and 29$) were found in control 
animals receiving only saline. Similarly, although blood lactate 
concentrations in phenformin-treated rats tended to be higher than 
those of controls, the differences were not statistically significant.
Pretreatment with an inhibitor of drug hydroxylation, SKF 525-&* 
greatly increased the magnitude of the hypoglycaemic and hyperlactataemic 
actions of phenformin in starved rats (Fig. 2.5). The mean pentobarbitone 
sleeping time for rats receiving the inhibitor was greater than 4h, while 
that for a similar group of starved rats that did not receive SKF 525“A 
was 1.6h. All of the animals in the high dose group (O.375mmol/kg) 
died within 4h of administration of phenformin. A pronounced hyper­
lactataemia was apparent in these animals, much greater than that 
obtained even with a dose of 0*50mmol/kg in rats that had not received 
SKF 5 2 5 Blood glucose concentrations again fell sharply, even in 
control animals.
Table 2.1 Blood glucose and lactate concentrations in fed. 
unanaesthetised rats
BLOOD C0M3EHTRATI0F (m&l)
TB3E (h)
GUJCOSE 
MEAH ( S.E.M.)
LACTATE 
MEA2T ( S.E.M.) TIME (h)
0 5.3 (0.1) 3.5 (0.4) 0
2.25 5.2 (0.1) 3.2 (0.4) 2
6 4.9 (0.1) 3.9 (0.6) 6
Blood from 12 rats (l95-245g) was removed from the tail, 6 of the 
samples being used for glucose assay and 6 for lactate assay. The 
rats were restrained during blood sampling in a polythene cylinder, 
but were returned to their cage between samplings.
Pig* 2*4 Blood glucose and lactate concentrations in starved*
pentobarbitone-anaesthetised rats following intraperitoneal 
administration of phenformin:
BLOOD GLUCOSE (mM)
4
3
• **2
• - SIGNIFICANT POINTS
BLOOD LA.C TATE (mli)
2
1
m--m-
0
[________ |________I________ I_______ J-------- 1--------1------------------*— :--------------
0 1 2 3 4
TIME AFTER ADMINISTRATION OP PHENFORMIN (h)
Rats (l85-285g) were starved for 24h, then anaesthetised with Nembutal
(iml/kg i*p.)* About 0.2h later a blood sample was taken and phenformin
or saline administered* Points represent the combined group means of
two studies, with S*E*M*s in the range 0*1-0*4mM; (glucose} and 0*1-0*3mM
(lactate) * P^0*05, ** P<0.01 compared with control*
• Phenformin (0*375Bmol/kg i*p*) n*=6 o Saline n«3
• Phenformin (0*50mmol/kg i*p*) n«7 □ Saline n«5
Fig, 2.5 31ood glucose and lactate concentrations in starved rats 
•pretreated with an inhibitor of microsomal drug hydroxylation, 
following intraperitoneal administration of phenformin
In two studies rats (2l0-240g) were starved for 23h or 24k 
and SKF 525“ -^ (0*14®mol/kg i*p*) was administered to inhibit micro­
somal drug hydroxy lation. At 0,8h the animals were anaesthetised 
with Uembutal (0.75ml/hg i.p.). At 1h a blood sample was taken from 
the tail* then phenformin or saline was administered, * P<0.05t 
** P^O,Olf *** p<0,001 compared with control.
■ Phenformin (O.25mmo3/kg i.p.) n=*3
a  phenformin (0.375®IBo3/hg i*P»)
□ Saline n»5
One animal in the low dose group died 2«5h after phenformin* 
and all the animals in the high dose group died between 2.5 and 4h 
after administration of phenformin.
BLOOD GLUCOSE
5
4
3
2
1
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BLOOD LACTATE (mM)
4
3
2
1
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Ether anaesthesia was associated with a pronounced hyperglycaemia 
in starved rats (Fig. 2.6). Administration of phenformin did not 
prevent this increase in blood glucose concentration hut caused a 
marked elevation in blood lactate concentration.
Chloral hydrate anaesthesia caused hypoglycaemia and hyperlac- 
tataemia in control rats (Table 2.2 )• These effects were additive 
with those of phenformin : the glycaemia of phenformin—treated animals 
dropped to very low levels, blood lactate concentrations were greatly 
elevated and the animals died within 2h.
Resting blood glucose concentrations in starved: rats anaesthetised 
with urethane were in the range 5~7*4niMt which is higher than expected 
for starved animals (3-4mM) and most were higher than the nominal
blood glucose concentration of fed animals. The glycaemia of control 
rats remained above 5»6mM for 4h. Phenformin, however, caused a sig­
nificant decrease in the mean blood glucose concentration to 3.1mM at 
4h, coincident with an increase in the blood lactate concentration 
(Fig. 2*7). The development of hyperglycaemia in starved rats following 
administration of urethane was apparent when blood samples were taken 
immediately after the induction of anaesthesia (Fig. 2.8). Within 1*5h 
the blood glucose concentration of the rats had doubled. There was an 
indication of a small hyperlactataemia accompanying the hyperglycaemia, 
although this was not statistically significant.
When phenformin was administered before sodium pentobarbitone 
anaesthetic, it produced pronounced hypoglycaemic and hyperlactataemic 
effects (Fig. 2.9). The initial blood glucose concentration was signi­
ficantly decreased in phenformin-treated animals compared to that of 
the controls, and glycaemia continued to fall during the period of 
anaesthesia. The hypoglycaemia was coincident with hyperlactataemia, 
the initial mean blood lactate concentration of phenformin-treated
Pig. 2.6 Blood glucose and lactate concentrations in ether-
anaesthetised. starved rats following intra-peritoneal admini­
stration of phenformin.
BLOOD 
GLUCOSE 
(mM)
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3-5
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Rats (190-215g) were starved for about 24ht then briefly anaes 
thetised with ether to allow collection of blood from the tail 
Phenformin (O.25mmo3/kg i.p*) or saline was administered and 
further blood samples taken at intervals.
• Phenformin (n*3)
O  Saline (n*2)
Table 2.2 Blood glucose and lactate concentrations in starved rats 
anaesthetised with chloral hydrate. following intraperitoneal 
administration of phenformin,
BLOOD GLUCOSE (mM)
PHENFORMIN SALINE
TIME (h) 1 2 MEAN 1 2 MEAN
0 3*1 3*1 3.1 2.8 3.4 3.1
1 1.3 1.8 1.6 2.7 3.1 2 .9
1.5 0 0.6 0.3 1.3 2.3 1.8
2 - - - 1.3 2.2 1.8
BLOOD LACTATE (mM) 
PHENFORMIN SALINE
TIME (h) 1 2 MEAN 1 2 MEAN
0 2.6 2.5 2.6 2.2 2.2 2.2
1 4.1 2.8 3.5 2.1 2.0 2.1
1.5 - 4.2 - - 2.8 -
2 . - - - 3.3 2.5 2.9
Four rats (205-225g) were starved for 26*5h and then anaesthetised 
with chloral hydrate* Blood was sampled from the tail immediately 
before and at intervals after intraperitoneal administration of 
phenformin (0.50mmol/kg) or saline* Phenformin-treated animals 
died 1*5h after administration of the drug*
Pig* 2*7 r Blood glucose and lactate concentrations in 
urethane-anaesthetised* starved rats following iirtra— 
BLOOD GLUCOSE (mM) peritoneal administration of phenformin
7rr
4 -
BLOOD LACTATE (mM)
3
2
1
0
2*51 1*5 . -  - -
TIME AFTER ADMINISTRATION OP PHENFORMIN
Rats (250-290g) were starved for 24h» then anaesthetised with urethane 
(l8mmol/kg i.p.). After 1.5k a -blood sample was taken from the tail and 
phenformin or saline administered*
A Phenformin (0*50mmol/kg i*p*) n*3
A Saline n?«3
* P(0*05f **P(0.01f *** P<0.001 compared with control.
Pig. 2.8 Development of hyperglycaemia in the starved rat following
administration of urethane 
BLOOD GLUCOSE (mM)
8
7
6
5
4
3
BLOOD LACTATE (mM)
2 r
0 0-5 1 v
TIME AFTER ADMINISTRATION OP URETHANE (h)
Six rats (200-275g) were starved for 24h and anaesthetised with urethane 
(l4mmol/kg i.p.). A "blood sample was immediately taken from the tail and 
a further dose of urethane (7mmol/kg i«p«) was given 2h later.
** P<0.01, *** P<0.001 compared with Oh.
Pig. 2.9 Blood glucose and lactate concentrations in starved rats 
following intraperitoneal administration of phenformin
Rats (245-275g) were starved for 25h and anaesthetised with Sagatal 
(0.8ml/kg i«P») 0.8h after administration of phenformin or saline. 
At 1h a blood sample was taken from the tail and a small volume 
(about 0.5ml) of saline was administered intraperitoneally to all 
animals.
• Phenformin (0.50mmol/kg i.p.) n-4
O Saline n-4 
* P<0*05f ** P<0.01, *** p<0.001 compared with control.
s u o k j u  vjihjouocj j
BLOOD LACTATE (mM)
TIME AFTER ADMINISTRATION OF PHENFORMIN (h)
animals 'being almost double that of the control rats. During the period 
of anaesthesia lactataemia increased in rats given phenformin but 
rapidly fell to a basal level in control rats, so that 4h after the 
administration of the biguanide the mean blood lactate concentration 
of the control group was only 25$ of that of the phenformin-tTeated group 
Resting blood glucose concentrations of anaesthetised rats were 
lower than those of cannulated, unanaesthetised rats (3.0t0.2mM com­
pared with 3.8i0.2mM, P<0.01 ). Resting blood lactate concentrations 
(l.7±0.2mM compared with 0.7±0.1mM, P<0.01) and blood 3 -hydroxybutyrate 
concentrations (l.24i0.19mM compared with 0.67±0.09mM, P<0.05) were 
higher in anaesthetised animals than in unanaesthetised. In conscious 
ratB phenformin produced a distinct hypoglycaemia lasting for 2h? 
hyperlactataemia which did not subside within 4h, and a marked decline 
in the blood concentration of 3-hydroxybutyrate (Figs. 2.10, .2.11 and 
2.12). In anaesthetised rats, however, there was no clear hypoglycaemic 
or hypoketonaemic phase, although a moderate increase in blood lactate 
concentration was apparent.
2.3.2 Studies in streptozotocin-diabetic rats
About 24h after administration of streptozotocin the blood glucose 
concentrations of fed rats were generally in the range 14-25^* Only 
animals in this 'moderately-diabetic* range were considered when 
assessing the results. Diabetic animals appeared generally healthy and 
streptozotocin itself never caused any deaths, although there was usually 
an overnight decrease in their body weights. In,diabetic rats there 
appeared to be a' threshold dose of about 0.5mmol/kg i.p. below which 
phenformin did not cause hypoglycaemia - indeed, at doses below the 
threshold there were indications of a small hyperglycaemic action 
(Fig. 2.13). At doses above the threshold, there was a marked lowering
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of the blood glucose concentration that persisted for the course of 
the experiment* The response of the blood lactate concentration to 
administration of phenformin was more clearly dose-dependent, with 
peak lactate concentrations decreasing in the order 0*56 to O*25mmol/kg 
(Pig* 2.14)* In contrast to the long-lasting hypoglycaemia the hyper­
lactataemia was transitory and by 3h blood lactate concentrations were 
falling towards the control level*
2*3*3 Comparison of some blood metabolite concentrations of fed* 
starved and streetozotocin-diabetic rats
Starvation led to a 5 reduction in the blood glucose concen­
tration and hepatic glycogen was almost completely depleted (Pigs*
2*15 and- 2*16)* The blood glucose concentration of diabetic rats was 
about double that of fed animals although the liver glycogen content 
was decreased to of the fed rat level* Both starvation and diabetes 
caused significant decreases in lactataemia in comparison with that of 
fed animals y and the blood lactate concentration of starved rats was 
significantly lower than that in diabetic rats* The mean blood pyru­
vate concentration of rats after a period of starvation was lower than 
that of diabetic rats but, because the fall in blood lactate was pro­
portionately greater, the blood lactate/pyruvate ratio of starved rats 
was lower than in diabetic rats* Starvation also caused a 3C$ decrease 
in the blood alanine concentration and large increases in the blood 
concentrations of 3-hydroxybutyrate and acetoacetate* Diabetes pro­
duced an elevation in blood acetoacetate concentration but not in 
3 —hydroxybutyrate concentration, so that the blood 3-bydroxybutyrate/ 
acetoacetate ratio of diabetic animals was significantly lower than 
that of either fed or starved animals* Circulating concentrations of 
ATP were lower in starved and diabetic rats than in fed animals,
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although the decrease was only significant in the diabetic animals.
The mean non-esterified fatty acid concentration, in serum from 
starved rats was nearly three times that of fed animals, and starva­
tion also produced a small hut significant fall in serum cholesterol 
concentration (Fig. 2.17)•
Fed, starved and diabetic rats gave different types of responses 
to an intraperitoneal glucose load (Fig. 2.18). In fed rats the peak 
glucose concentration occurred at 0.5h and the basal level was regained 
at 1h followed by a significant hypoglycaemic phase at 1.5-3h. The 
blood glucose concentration of starved rats also peaked at 0.5h after 
glucose loading, but the fall in glycaemia was slower and the glucose 
concentration was still significantly elevated above the basal level 
at 3h. In diabetic rats the peak blood glucose concentration was 
reached at 2h followed by a gradual decrease. The areas under the 
curves bordered by the basal blood glucose concentrations were in the 
ratio 1 : 4 * 9  for fed, starved and diabetic rats respectively, 
reflecting decreased uptake of glucose into the peripheral tissues 
in starved and diabetic animals.
2.4 Discussion
It is not easy to obtain resting values for blood metabolites 
such as pyruvate and lactate since the slightest struggling of the 
animal, such as occurs during sampling of blood from the tail of a 
rat, leads to increases in their concentrations (Goodwin and Williams, 
1952). Although blood glucose concentrations of fed rats remained 
fairly stable and close to a value generally accepted as "normal”, 
blood lactate concentrations were much higher than normal (Table 2.1). 
The hyperlactataemia was presumably due to a stress-mediated release 
of adrenaline causing breakdown of muscle glycogen. Thus it was 
necessary to use an anaesthetic- before serial sampling of blood,
Fig# 2*17 Serum non-esterified fatty acids (flEFA) and cholesterol 
concentrations in fed (F) and starved (s) rats
0-9
0-8
0-7
0 -6 -
0-5
0*4
0-3
0-2
0-1 -
SERUM UEFA (mM)
1-8
1-5-
1-2
0-9
0*6-
0-3
SERUM CHOLESTEROL (mM)
F S F S
Fed and starved rats were anaesthetised with sodium pentobarbitone and 
blood sampled from the heart# Serum was obtained by centrifuging the 
blood after it had been left to clot# Other details as in the legend 
to Fig. 2.15.
Fig. 2.18 Intraperitoneal glucose tolerance of fed# starved and strept- 
ozotocin-diabetic rats
Fed rats (235“270g) were anaesthetised with sodium pentobarbitone 0.8h 
after the intraperitoneal administration of a small volume (about 0.5ml) 
of isotonic saline. A blood sample was taken from the tail and glucose 
was administered (8.3mmol/kg i.p.). Other rats (l65-225g) were starved 
for about 24h before anaesthesia, and diabetic rats (220-235g) were used 
24h after administration of streptozotocin.
□ Fed (n=»5)
■ Starved (n»6)
A Diabetic (n»3)
*■* p^O.01, *** P(0*001 compared with basal value of same group (Oh).
BLOOD GLUCOSE (mM)
24
20
12
321
TIME AFTER ADMIBISTRATIOIT OF GLUCOSE (h)
although anaesthetised animals show gross changes in the levels of 
metabolites within cells or in the blood (Macdonald and Wann, 1978)*
A comparison was made of the effects on blood glucose and 
lactate concentrations of several anaesthetics commonly used with 
small animals • Ether anaesthesia of starved rats was accompanied by 
a marked hyperglycaemia (Pig. 2.6), an effect found previously in both 
fed and starved rats (Biebuyck and Alberti, 1972; Aynsley-Green et 
al.. 1973). This hyperglycaemia masked any hypoglycaemic action of 
phenformin. Blood lactate concentrations of control rats were high 
for starved animals, and phenformin increased them further. The 
hyperglycaemic action of ether is mediated by its action on the 
sympathetic nervous system causing release of catecholamines (Clarke, 
1973).
Chloral hydrate caused hypoglycaemic and hyperlactataemic 
effects that were additive with those of phenformin (Table 2.2.) and 
the animals died soon thereafter. Conversely, chloral hydrate caused 
hyperglycaemia in starved, glucose—loaded rats (Dulin, 1965)*
Urethane caused pronounced hyperglycaemia and a slight hyper- 
lactataemia in starved rats (Pig. 2.8). A rise in the glycaemia of 
starved rats — from 3.2 (l'O.l)mM to 9*3 (+0.4)mM after 1h — was noted 
after a dose of urethane similar to that used in the present study 
(Reinert, 1964). It is thought that the hyperglycaemic action of 
urethane is due to hypothalamic activation resulting in indreased 
sympathetic discharge and enhanced adrenaline secretion from the 
adrenal medulla, although adrenocorticotrophic hormone and the corti­
costeroids seem also to be involved (Ondo and Kitay, 1973; Reinert, 
1964; Krzemien and Lipowska-Zabawska, 1976). When urethane anaes­
thesia was compared with pentobarbitone anaesthesia of fed rats, 
liver and muscle glycogen concentrations were lower and blood glucose
and lactate concentrations were higher in the urethane group (Hepburn 
et al.. 1978). Thus although urethane anaesthesia of starved rats 
allowed phenformin to exert narked hypoglycaemic and hyperlactataemic 
effects (Pig. 2.7),because of its profound actions on carbohydrate 
metabolism it was considered unsuitable for further study. Instead, 
sodium pentobarbitone was chosen as the anaesthetic for use in the 
animal model of phenformin-induced hyperlactataemia, although it too 
may change the blood glucose concentration.
Pentobarbitone anaesthesia generally causes hyperglycaemia in 
fed rats (Biebuyck and Alberti, 1972? Purner et al., 1972? Aynsley- 
Green et al.. 1973) but no change'in the blood glucose concentration 
of starved animals (Reinert, 1964? Biebuyck and Alberti, 1972? 
Aynsley-Green et al.. 1973). In a comparison of unanaesthetised and 
pentobarbitone-anaesthetised rats, however, it was found that pento­
barbitone anaesthesia of starved animals caused a decrease in blood 
glucose concentration and increases in blood lactate and 3-hydroxy- 
butyrate concentrations (Pigs. 2.10 - 2.12). Barbiturates block the 
oxidation of HA35H at the HADH dehydrogenase stage of the mitochon- ( 
drial electron-transport chain (Cohen and Marshall, 1968? Macdonald 
and Wann, 1978? Weiss et al.. 1978) and this inhibition may be the 
basis of the hypoglycaemic action of pentobarbitone seen in starved 
rats, an increased rate of glycolysis causing increased uptake of 
glucose by the peripheral tissues. Accumulation of RADH in the mito­
chondria would be expected to lead to increased tissue and blood con­
centrations of lactate and 3-hydroxybutyrate, the products of the 
redox reactions of UADH with pyruvate and acetoacetate respectively. 
Pentobarbitone anaesthesia caused a rapid fall in the blood pyruvate 
concentration of rats and rabbits, with a concomitant increase in 
blood lactate (Goodwin and Williams, 1952). In general, however,
barbiturate anaesthesia causes increases in tissue concentrations of 
glucose and ATP and decreases in lactate and pyruvate levels (Gatfield 
et al., 1966; Marquez-Julia and French, 1968? Kinoshita et al., 19^9? 
Kinoshita et al., 1970? Dodge and Takemori, 1972). Most of these 
studies were done using brain, in which barbiturate anaesthesia is 
considered to cause a high energy state characterised by inhibition 
of the energy-consuming processes. This inhibition leads to a rise 
in the concentrations of high energy compounds such as phosphocre- 
atine and ATP and a decrease vin the HADE/HAD* and lactate/pyruvate 
ratios (Ksi|zak, 1976). In the whole animal, however, the action of 
pentobarbitone anaesthesia, as indicated by changes in blood meta­
bolite concentrations, appears to be to accelerate anaerobic gly­
colysis, causing falls in blood glucose and pyruvate concentrations 
and increases in blood lactate and 3-hydroxybutyrate concentrations. 
Pentobarbitone was chosen as the anaesthetic for use in the animal 
model because its effects on carbohydrate metabolism were not as 
severe as those caused by ether, chloral hydrate or urethane. It 
was realised, however, that care would be needed when drawing con­
clusions about the mechanism of action of phenformin from the results 
of experiments involving pentobarbitone anaesthesia.
Phenformin did not cause significant hypoglycaemia or hyper— 
laetataemia in starved, pentobarbitone-anaesthetised rats (Fig. 2.4)? 
in agreement with the results of others who reported no change or only 
small decreases in blood glucose concentration in starved rats fol­
lowing singles doses of phenformin of 0.21 or 0.42 mmol/kg i.p. 
(Muntoni et^al., 1970? Cook et al., 1973ai; Tutwiler, 1978), 0.04 - 
0.42 mmol/kg s.c. (Altschuld and Kruger, 1968? Gulbenkian et al., 1973? 
Polacek and Ouart, 1974), 4 mmol/kg p.o. (Blickens and Riggi, 1971) or 
0.21 ramol/kg/h infused intravenously for 2.5h (Holloway and Alberti,
1975) — se© Table 1*2. Blood lactate concentrations were measured in 
two studies and found to be increased following administration of 
phenformin (Blickens and Riggi, 1971? Holloway and Alberti, 1975)•
Inhibition of the metablism of phenformin to pharmacologically 
inactive 4-hydroxyphenformin greatly increased the magnitude of its 
hypoglycaemic and hyperlactataemic effects in starved rats (Fig. 2.5). 
Such inhibition, coupled to infusion of glucose, has been used to 
produce hyperlactataemia in starved rats, and blood lactate concen­
trations of 14.4mM (Holloway and Alberti, 1970» 7«3mM (Alberti and 
Holloway, 1977) and 10.QsiM(Holloway and Alberti, 1977) have been 
obtained. Similarly, inhibition of microsomal drug hydroxylation 
caused an increase in the hypoglycaemic effect produced by phenformin, 
from 10$ to 35$ (Cook et al.. 1973a). Although inhibition of micro­
somal drug hydroxylation increased the magnitude of the hypoglycaemic 
and hyperlactataemic effects of phenformin, confirming that phenformin 
and not a hydroxylated metabolite is the active metabolite, such in­
hibition was considered unsuitable for use in the animal model since 
it is unphysiological and also might interfere with the metabolism 
of potential antihyperlactataemic agents given with phenformin.
Pronounced hypoglycaemic and hyperlactataemic effects were seen 
when phenformin was administered before the sodium pentobarbitone 
anaesthetic (Fig. 2.9). The reason why phenformin is pharmacologi­
cally active in unanaesthetised but not in pre-anaesthetised animals 
is uncertain, but it may be due to the increase in blood flow to the 
liver caused by barbiturate anaesthesia (Hiley et al., 1978). An 
increase in hepatic blood flow would increase the "first pass” effect 
after oral and intraperitoneal administration of a drug such as phen­
formin which is metabolised rapidly by the liver. Thus after a given 
dose of phenformin the amount of pharmacologically-active drug reaching
the tissues would he greater in unanaesthetised than in pentobarbitone- 
anaesthetised animals* Alternatively pentobarbitone and phenformin 
could be acting at the same locus and in anaesthetised animals phen— 
formin might be prevented from interacting with the receptors as 
effectively as it does in unanaesthetised animals.
Phenformin had antidiabetic and hyperlactataemic actions in 
anaesthetised, streptozotocin-diabetic rats (Figs. 2.13 and 2.14). 
Similar decreases in blood glucose concentration following admini­
stration of phenformin have been found in alloxan-diabetic rats / 
(Ruggles et al.. 1968? Blickens and Riggi, 1971) and. streptozotocin- 
diabetic rats (Holloway and Alberti, 1975) - see Table 1.3. It was 
considered that the streptozotocin-diabetic rat provided a suitable 
model for study of biguanide-induced hyperlactataemia and that an 
intraperitoneal dose of phenformin of 0.5 mmol/kg gave hypoglycaemic 
and hyperlactataemic effects of suitable magnitude. For later experi­
ments in which small increases in blood glucose concentration were to 
be measured, however, a starved rat model with the phenformin admini­
stered before the anaesthetic was thought to be more appropriate, 
because of its much lower basal blood glucose concentration.
A comparison of some blood metabolite concentrations of control 
fed, starved and streptozotocin-diabetic rats (Figs. 2.15 - 2.17) 
with those of some human maturity-onset diabetics (Stacpoole et al., 
1976? Stacpoole et al.. 1978) showed that the diabetic animal model 
is the closest to the metabolic state of humans with the diabetic con­
dition which phenformin is used to treat. Mean blood concentrations of 
glucose, lactate, alanine and 3-hydroxybutyrate for the human diabetics 
were quoted as 12.51 1*4» 0*43 and 0.26mM respectively, compared with 
16.8, 2.0, 0.22 and 0.34nM for streptozotocin-diabetic rats. The mean 
plasma cholesterol concentration of the human diabetics was 0.62mM.
Other findings in streptozotocin-diabetic rats characteristic of 
human maturity-onset diabetes are a prolonged recovery time after 
an intraperitoneal glucose load (Fig# 2.18), indicative of a lowered 
plasma insulin concentration, and a reduced liver glycogen content 
(Fig. 2.16).
CHAPTER 3
METABOLIC EFFECTS OF SODIUM DICHLOROACETATS 
ADD ITS INTERACTIONS WITH PHEHFORMHT ID 
STARVED ADD ID STREPTOZOTOCIN-DIABETIC RATS
3*1 Introduction
Sodium dichloroacetate is an hypoglycaemic agent which is active 
when given orally?with potential use in the prevention and reversal of 
lacticacidosis produced hy phenformin in some diabetics. It has under­
gone preliminary clinical trials as an antidiabetic agent in its own
right (Stacpoole et al.. 1978)*
In starved rats, dichloroacetate caused an increase in the blood
concentration of ketone bodies as well as falls in blood glucose and
lactate concentrations (Blackshear et al.. 1974). One of its mechanisms 
of biochemical action in the starved animal is the activation of pyruvate 
dehydrogenase in liver and peripheral tissues (Whitehouse et al.« 1974). 
In the present study, an attempt was made to correlate activation of 
pyruvate dehydrogenase with changes in the blood concentrations of 
glucose, lactate, pyruvate and ketone bodies and with changes of hepatic 
glycogen content, at 1»5i 3 and 5 hours after oral administration of a 
large dose (6.6 mmol/kg) of dichloroacetate.
The metabolic effects of orally-administered sodium dichloro— 
acetate were also studied in streptozotocin-diabetic rats, using a 
range of doses of 1 - 8 mmol/kg. In diabetic rats intravenous infusion 
of dichloroacetate caused a small decrease in glycaemia but little 
change in the blood lactate concentration (Blackshear et al., 1975©-) 
Blood ketone body concentrations were decreased, so that some of the 
metabolic effects of dichloroacetate in diabetic animals appear to be 
different to those in starved animals. The activity of pyruvate dehy­
drogenase was measured in tissues taken from streptozotocin-diabetic 
animals, to determine whether its activation is implicated in the 
metabolic effects of dichloroacetate in this animal model.
Sodium dichloroacetate prevented or decreased the hyperlactat- 
aemia caused by phenformin in fed rats (Guest, 1980), starved rats
(Holloway and Alberti, 1976) and streptozotocin-diabetic rats 
(Holloway and Alberti, 1975? Kuhnle et al., 1977? Man and Alberti,
1977)* In these studies dichloroacetate was given intraperitone- 
ally or intravenously, although if dichloroacetate is to be given in 
combination with phenformin pral-.administration would be more, appropriate. 
The molar ratios of dichloroacetate/phenformin needed for the aboli­
tion of, or a large reduction in, the hyperlactataemia produced by 
phenformin were in the range 2-12.
In the present study various doses of sodium dichloroacetate 
were administered orally to streptozotocin-diabetic rats to determine 
a dose which prevents the hyperlactataemia produced by an intraperi— 
toneal dose of phenformin of 0.5mmol/kg. The metabolic interactions 
of phenformin with dichloroacetamide, also an activator of pyruvate 
dehydrogenase (Whitehouse et al., 1974), were also examined, and low 
doses of phenformin and dichloroacetate were used in combination in 
an attempt to produce an additive hypoglycaemic effect without 
hyperlactataemia.
3.2 Materials and Methods
3.2.1 Chemicals
Sodium dichloroacetate was prepared by neutralising dichloro- 
acetic acid (Hopkin and Williams, Chadwell Heath, Essex) with sodium 
hydroxide. The salt was obtained by shell-freezing the solution in 
a bath of methanol at -45°C an& freeze-drying at -60°C in a Virtis 
10-146 freeze-drier (Virtis, Gardiner, Dew York, U.S.A.). In some 
experiments a 0.671*1 aqueous solution of sodium dichloroacetate 
was used, and this solution and dichloroacetamide were supplied by 
Sterling-Winthrop Research Laboratories, Fawdon, Newcastle.
Sodium [l-,ffC ] pyruvate (lO.7-l3.3mCi/mmol) was obtained as a 
freeze-dried solid sealed under nitrogen (Radiochemical Centre,
Amersbam, Buckinghamshire). Since aqueous solutions of sodium pyru­
vate are unstable, upon receipt a 5O/uCi ampoule was made up to 25ml 
with distilled water and 1ml of the solution was transferred to each 
of 25 freeze-drying vials. After freezing for about 24h at -20°C, 
the solutions were freeze-dried overnight at -80°C in an Edwards 
Pirani 11 freeze-drier (Edwards High Vacuum, Crawley, Sussex). The 
vials were stored at -10°C until use. Bovine serum albumin (essen­
tially fatty acid free, from fraction V albumin), DL - dithiothreitol, 
sodium pyruvate, /? -phenylethylamine and thiamine pyrophosphate 
chloride were obtained from Sigma Chemical Company, Poole, Dorset.
The disodium salt of coenzyme A was supplied by British Drug Houses, 
Poole, Dorset and the scintillant fOmnifluor, (a blend of 98$ PPO 
and 2$ Bis-MSB) was obtained from New England Nuclear, Boston, 
Massachusetts, U.S.A. Other chemicals, enzymes and assay kits were 
from the sources specified in chapter 2.
3.2.2 Materials
Autoanalyser cups pre-filled with fluoride and oxalate were 
supplied by Stayne Laboratories Ltd., Marlow, Buckinghamshire.
Gelatin capsules (size 0) were donated by Eli Lilly and Company, 
Basingstoke, Hampshire and glass fibre filter paper was obtained 
from British Drug Houses.
3.2.3 Animals
Adult male Wistar albino rats were used in all experiments.
The rats were starved or rendered diabetic by intravenous admini­
stration of streptozotocin, as described in 2.2.3.
Administration of compounds
Sodium dichloroacetate (6.7mmol/kg p.o.) was administered to 
starved rats as a O.67M aqueous solution. It was administered 
orally to streptozotocin-diabetic rats at doses of 1, 2, 4 and
8mmol/kg, as 0*5* 1*2 and 4M solutions in distilled water. In 
studies of the metabolic interactions of phenformin and sodium 
dichloroacetate, the dichloroacetate was administered orally at 
doses of 0.5* 1, 1.3, 2, 3 and 4mmol/kg as 0.1, 0.2, 0.26, 0.4,
0.6 and O.67M solutions in distilled water.
Dichloroacetamide was administered orally at doses of 1, 2 
and 4mmol/kg, as 0.2, 0.4 and 0.6M solutions in distilled water. 
Control animals received similar volumes of distilled water. Phen— 
formin was administered intraperitoneally at doses of 0.25, 0*375 
and 0.50mmol/kg, as 0.13* 0.19 and O.25M solutions in O.15M saline. 
Collection of blood and tissue samples
Blood from starved animals was collected from the heart by 
cutting the diaphragm and inserting a syringe needle into a ven­
tricle. About 0.5ml of the blood was preserved in a fluoride/ 
oxalate cup and an aliquot taken later for assay of glucose. The 
remainder of the blood was immediately deproteinised by addition to 
an equal volume of ice-cold 0.7M perchloric acid and the supernatant 
treated as described in 2.2.3. Blood from diabetic animals was 
obtained from the inferior vena cava and treated as described for 
blood from starved rats. After exsanguination organs were rapidly 
removed and freeze-clamped with tongs cooled to the temperature of 
liquid nitrogen, in the order liver (large lobe), heart, epididymal 
adipose tissue, right kidney and skeletal (femoral) muscle. The 
tissues were kept in liquid nitrogen until the determination of 
pyruvate dehydrogenase activity and liver glycogen content. In 
studies of the metabolic interactions of phenformin with sodium 
dichloroacetate or dichloroacetamide blood was obtained from the 
tail vein, as described in 2.2.3.
3.2.4 - Assay Methods
Blood metabolites and liver glycogen were measured By the 
methods described in 2•2.5*
Pyruvate dehydrogenase activity was measured in crude tissue ■ 
homogenates using a method Based on that developed By Taylor et al. 
(1973) for adipose tissue homogenates. The ^CO2*evolved from 
sodium [l-^c]pyruvate in the pyruvate dehydrogenase reaction was 
absorbed in jS-phenethylamine and the resulting solution was counted 
in a liquid scintillation counter. The reaction was carried out in 
a 10ml Erlenmeyer flask fitted with a glass centre well. A gelatine 
capsule (size 0) containing 0.2ml ft-phenethylamine and a strip of 
glass fibre filter paper (1cm x 2cm) was placed in the well, while 
the main chamber of the flask contained 0.3ml of an assay mixture 
comprising 1.2mM EDTA, magnesium chloride, 2$ bovine serum
albumin, 1.3mM DL-dithiothreitol, 0.27mM coenzyme A, 2.7m& HAD+,
0.13mM thiamine pyrophosphate and 1.OmM sodium pyruvate in 12mM 
potassium hydrogen phosphate buffer, pH 7*4* Homogenising buffer 
(imM EDTA, 1mM DL-dithiothreitol, 1$ bovine serum albumin in 10mM 
potassium hydrogen phosphate buffer, pH 7*4) was also added to the 
main chamber, the volume depending on the aliquot of homogenate used. 
Immediately before incubation 0.1ml of 4eM hydrochloric acid was 
added to a vial containing 2/iCi of sodium [l— ^c] pyruvate, and 5jul 
of the solution was added to the main chamber of the flask. Tissue 
was removed from liquid nitrogen and immediately hand—homogenised in 
an appropriate volume of ice-cold homogenising buffer. Aliquots of 
homogenate of 0.2ml, 0.1ml and 0.05ml were used in the assay and 
preliminary experiments were done to determine the concentrations 
of homogenate of each tissue that gave proportional increases in
activity as the sample volume was increased* After addition of assay 
mixture, homogenising buffer and sodium [l— ^ c]pyruvate solution to the - 
main chamber, the flask was incubated in a shaking water bath at 37°C 
for 3min* The homogenate was then added, the flask was closed with a 
rubber bung and incubation continued for 2min. The reaction was 
stopped by the addition of 1ml of ice-cold acidic buffer (0*08M citric 
acid, 0.04M disodium hydrogen phosphate, pH 3..0) and incubation con­
tinued for about 30min* The capsule was removed from the well and 
placed in. 4«5®1 of a toluene-^ethanol. (9*1» -v/v)- scintillation, fluid 
(0*4$ Omnifluor)* The radioactivity was measured in a liquid scin­
tillation counter (LKB 1210, Wallac Ultrobeta; LKB Instruments Ltd., 
Croydon, Surrey).
The activity of pyruvate dehydrogenase was calculated in units/ 
g tissue, where one unit produces 1/tmol of C02 -in one minute under 
the assay conditions used.
Analysis of data
The statistical significance of differences found between group 
mean values was assessed using Students t-test or the d-test, as 
described in 2.2.5* ike figures points or bars represent the group 
mean with the standard error of the mean being shown by vertical lines. 
In groups containing only two observations the points represent the 
individual values.
3*3 Results
3.3.1 Metabolic effects of dichloroacetate in starved and diabetic rats 
Oral administration of sodium dichloroacetate decreased the blood 
glucose concentrations of starved and of streptozotocin-diabetic rats 
(Pig. 3*1 and 3*6). The percentage decrease was greater in starved 
rats (23—46%) than in diabetic rats (9—18%)» although the absolute 
change in blood glucose concentration was usually greater in diabetic
Pig* 3«1 Blood glucose and he-patic glycogen concentrations of 
starved rats following oral administration of sodium dichloroacetate
Rats (l80-275g) were starved for 23«5-25«5k &nd sodium dichloroacetate 
(6*7mmol/kg) was administered by gavage* Control animals received 
appropriate volumes of distilled water* After 1.3h, 2*8h and 4«8h 
the animals were anaesthetised with sodium pentobarbitone and at 
1*5h, 3h and 5k after administration of the dichloroacetate blood 
was sampled from the heart and tissues were freeze-clamped*
Time after No* of
Administration (h) observations
1*5 DICHLOROACETATE (D) 4-7
WATER (W) 4-6
3, 5 DICHLOROACETATE (D) 3
WATER (W) 3
(except where the range is 
indicated - 2 observations
* P < 0.05, ** P < 0.01, *** P < 0.001
compared to control at same time of administration.
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rats. In diabetic rats the antidiabetic effect of dichloroacetate, 
1mmol/kg, (a decrease in blood glucose concentration of 17$ compared 
with controls) was similar to those at doses of 4 and 8mmol/kg (18$ 
and 17$ respectively). The hypoglycaemic effect of dichloroacetate 
in starved rats was long-lasting, reductions in mean blood glucose 
concentration of 23$, 37$ and 46$ being obtained at 1.5h, 3h and 5^ 
after its administration.
Sodium dichloroacetate also lowered hepatic glycogen levels in 
starved rats, though not to a statistically significant degree (Fig. 
3.1)• In diabetic rats, however, no clear decreases were apparent 
and a statistically significant increase in hepatic glycogen was 
obtained with a dose of dichloroacetate of 1mmol/kg (Fig. 3*6).
The hypoglycaemic action of dichloroacetate was associated 
with falls in the blood concentrations of pyruvate and lactate for 
both starved rats (Fig. 3*2) and diabetic rats (Fig. 3*6). The 
pyruvate-lowering effect was generally the more pronounced s in 
diabetic rats mean blood pyruvate concentrations were decreased by 
25-53$ while the mean blood lactate concentrations fell by only 
14-36$. In diabetic rats the decreases were apparently dose-related 
for doses of 2, 4 and 8mmol/kg, but the lowest dose (immol/kg) had 
effects similar in magnitude to those of the highest dose. In 
starved rats there was no clear time course for the lowering of 
blood lactate and pyruvate concentrations, mean decreases of 29$,
-5$ and 59$ being obtained for lactate and of 50$* 50$ and 39$ o^t 
pyruvate, at 1.5h, 3h and 5h consecutively.
Sodium dichloroacetate caused statistically significant 
increases in the blood acetoacetate concentrations of starved rats 
(Fig. 3«3) and of diabetic rats (Fig. 3*7) "but not in their blood
BLOOD
LACTATE
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Pig. 3.3 Blood 3—hydroxybutyrate and acetoacetate concentrations of 
starved rats following oral administration of sodium dichloroacetate
Legend as in Pig. 3.1
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3-hydroxybutyrate concentrations. In starved rats the increases in 
blood acetoacetate concentration were large - 103$. 165$ and 74$ at 
1*5h, 3h and 5h consecutively. Blood 3-hydroxybutyrate concentrations 
were also elevated at 1*5h and 3h, by 27$ and 59$ respectively but 
not to a statistically significant extent. Thus the effect of dich­
loroacetate on the blood concentrations of ketone bodies of starved 
rats appeared to peak about 3h after its administration, in contrast 
to the longer-lasting actions on blood glucose, lactate and pyruvate.
The blood 3-hydroxybutyrate/acetoacetate and lactate/pyruvate 
ratios were calculated from individual metabolite concentrations 
and the values used to deduce cytosolic and mitochondrial NAD+/
NADH ratios, assuming pH7.0 and equilibrium constants of 1.11 x
—11 —910 and 4*93 x 10 ' for the lactate dehydrogenase and 3-hydro—
xybutyrate dehydrogenase reactions respectively Williamson et al.,
1967). In starved rats cytosolic M D +/NADH ratios were unchanged
by dichloroacetate (437iS.E.M. of 72, n=8,compared to control,
447 ^ 53, n=*8) while mitochondrial NAD+/NADH ratios were increased
(3.2 0 i 0.30, n-11,compared to control, 1.4 5'£0*18, n=10;
P < 0.001).
In diabetic rats blood 3-hydroxybutyrate concentrations were 
unchanged following administration of dichloroacetate, except for 
a statistically significant decrease at a dose of 1mmol/kg, and 
blood acetoacetate concentrations were increased. Cytosolic 
M B +/NADH ratios, calculated using blood lactate/pyruvate ratios, 
were not affected by dichloroacetate (590 £ 69, n=*17, compared to 
control goup mean, 659^ 82, n=5)« As with starved rats, cal­
culated mitochondrial 11&D+/M3R ratios were increased follow­
ing administration of dichloroacetate (4*42 £ 1.36, n=3j 
4*58-1 *00, n®4, P=0.05; 5.20£1.29, n=5; 5.12 + 0.77, n=5,
P <0.05 for 1, 2, 4 and 8mmol/kg consecutively, compared with 
the control group mean of 2*531 0*43, u=5)*
The blood alanine concentrations of diabetic rats were de­
creased by dichloroacetate, the magnitude of the decrease being 
related to the dose of dichloroacetate (Fig. 3*7)*
Sodium dichloroacetate activated pyruvate dehydrogenase in 
tissues of starved rats (Figs. 3.4 and 3.5) and diabetic rats 
(Fig. 3.8). In starved rats the pyruvate dehydrogenase was 
clearly elevated in liver, less so in femoral muscle and heart 
and only marginally in kidney. In diabetic rats liver pyruvate 
dehydrogenase was activated to a degree that was related to the 
dose of dichloroacetate administered. Activation was also appa­
rent in kidney and heart but because of the small sample size 
statistical comparisons were not possible. Combining all dich— 
loroacetate-treated animsls, however, gave a mean kidney pyruvate 
dehydrogenase activity of 1.30£ 0.31units/g fresh^wt., n=8 (com­
pared with control group mean 0.64^ 0.21units/g fresh wt., n=»3) 
and a mean heart pyruvate dehydrogenase activity of 1.97 — 0*37 
units/g fresh wt., n=6) compared with the control group mean 
O.7O £ 0.33units/g -fresh wt., n=3 J P 4.0.O5) • Epididymal adipose 
tissue and femoral muscle pyruvate dehydrogenase activities in 
diabetic animals were very low and were not increased following 
administration of dichloroacetate — for adipose tissue a mean 
activity in treated rats of 0.06 £0.02units/g-fresh wt., n=8,com­
pared with a control mean of 0.06£0.03units/g fresh wt., n=3}for 
skeletal muscle 0.09£ 0.03units/g. fresh wt., n=6 compared with the 
control mean of 0.09 £0.03units/g fresh wt'., n=3.
3.3*2 Interactions of dichloroacetate with uhenformin
Phenformin and dichloroacetate did not have a pronounced additive
Pig* 3*4 Liver and kidney -pyruvate dehydrogenase activities in starved 
rats following oral administration of sodium dichloroacetate
Legend as for Pig. 3*1
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Pig. 3.5 Heart and femoral muscle pyruvate dehydrogenase activities 
of starved rats following oral administration of sodium dichloroacetate
Legend as in Pig. 3.1
HEART PYRUVATE
DEHYDROGEHASE
ACTIVITY
(UMITS/g PRESH WT.)
5
4
3
2
1
51-5 3
TIME AFTER ADMUttSTRATIOH (h)
0-6
FEMORAL MUSCLE 
PYRUVATE DEHYDRO­
GEHASE ACTIVITY
(UHITS/g PRESH WT.^
0-2
1-5 3 5
TIME AFTER ADMHJISTRATI01T (h)
Pig. 3.6 Blood glucose, lactate and pyruvate concentrations and hepatic 
glycogen content of streptozotocin-diabetic rats following oral admini­
stration of soditun dichloroacetate
Rats (220-265g) were rendered diabetic by the intravenous administration 
of streptozotocin and 24-27»5k later sodium dichloroacetate (l-8mmol/kg) 
was administered by gavage. Control animals received distilled water 
and doses were randomised over the two days of the study. After 1.8h 
the animals were anaesthetised with sodium pentobarbitone and at 2h 
blood was sampled from the tail for glucose and lactate assays and from 
the inferior vena cava for pyruvate, alanine and ketone body assays.
A small sample of liver was taken for assay of glycogen and liver and 
other tissues were freeze-clamped in liquid nitrogen prior to estimation 
of pyruvate dehydrogenase activity.
Bose of dichloroacetate (mmol/kg p.o.) no. of observations 
0 5
1 3
2 4
4 5
8 5
* P < 0.05, ** P < 0.01, *** P < 0.001
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hypoglycaemic action in streptozotocin-diabetic rats, even when low
doses of the two compounds were given (Table 3*1), although the blood glucose
glucose concentrations of the rats on combined treatment were generally
lower than those not receiving dichloroacetate. Dichloroacetate,
however, lowered resting blood lactate concentrations, and decreased
the hyperlactataemia produced by phenformin (Table 3*2). For complete
suppression of biguanide-induced hyperlactataemia, a molar ratio of
dichloroacetate/phenformin of 8 was required (Fig. 3*9)» High doses
of dichloroacetate caused hyperketonaemia in diabetic animals, with
blood 3-hydroxybutyrate concentrations being elevated to over 30C$
of those found in animals receiving only phenformin (Table 3*2).
Dichloroacetamide prevented phenformin-induced hyperlactataemia, a
molar ratio dichloroacetamide/phenformin of 4 completely preventing
the increase in blood lactate concentration normally obtained with
phenformin (Fig. 3*10). Oral doses of dichloroacetamide of 1 and 4
(though not 2)mmol/kg caused hypoglycaemic effects that were greater
than that observed with phenformin alone. The magnitude of the hypo—
glycaemic response obtained in animals receiving only phenformin was,
however, smaller than that obtained in previous experiments.
3*4 Discussion
A large oral dose (6.7mmol/kg) of dichloroacetate to starved 
rats (Fig. 3*1) caused hypoglycaemia of a magnitude similar to that 
obtained previously with intraperitoneal dosing (3mmol/kg, 45$ 
decrease, Whitehouse et al.« 1974? 2mmol/kg, 25$ decrease, Goodman 
et al., 1978) and intravenous dosing (8mmol/kg, 25$ decrease, Black- 
shear et al., 1974)• A similar degree of hypoglycaemia was found in 
experiments in which dichloroacetate was given subacutely (3*5mmol/^cs/^ 
p.o. for 14d, 20$ decrease, Misbin, 1979? 3#3mmol/k^d i.p. for 7<i,
55$ decrease, Hayek andWoodside, 1980). It seems, therefore, that
Table 3.1 . Blood glucose concentrations in streotozotocin-diabetic
rats following administration of dichloroacetate and -phenformin
BLOOD GLUCOSE C0NCEUTRATI02J (mM)
TIKE AFTER 
PHEHFOHMUT 
00
DICHLOROACETATE
+
PHEHFORMUT
(n*4)
DICHLOROACETATE
+
SALIHE
(n-3 )
WATER
+
PHEHFORMUJ
(n=3)
0
14.5 14.6 15.6
±0.3 ±0.4 ±0.6
13.9 14.7 14*6
1
±0.4 ±0.3 ±0.4
14.3 15.5 14.5
2
±0.3 ± 1.0 ±0.1
14.5 14.2 15.0
3
±0 .4 ±0.9 ±0.9
14.7 13.3 14.8
4
±0.5
ON.o
4-1 ± 0.6
Rats (l80-220g) were rendered diabetic by intravenous administration 
of streptozotocin and 23h later sodium dichloroacetate (immol/kg) was 
administered by gavage. Other animals received distilled water. After 
0.8h anaesthesia was induced by sodium pentobarbitone and at 1h the 
animals received phenformin (O.375n>niol/kg i.p.) or saline. Blood was 
sampled from the tail.
Results as group mean ± S.E.M.
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rig. -Blood glucose and lactate concentrations of
streptozotocin-dia'betic rats following administration of 
sodium dichloroacetate (4mmol/kg p.p.) and T>henformin ( i 
or water and -phenformin fCp
Legend as for Table 3.2
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Pig* 3*10 Blood glucose and lactate concentrations of streptozotocin- 
diabetic rats following administration of dichloroacetamide and phenformin
Rats (l80-225g) were rendered diabetic by intravenous administration of 
streptozotocin and 23-25h later dichloroacetamide was administered by 
gavage* Control animals received distilled water* After 0.8h,anaesthesia 
was induced by sodium pentobarbitone and at 1h all animals received phen- 
formin (0*5mmol/kg i.p*)* Blood was sampled from the tail*
Bose of dichloroacetamide ffo* of animals
(mmol/kg p*o*)
0 O 7
1 ▲ 3
2 ■ 4
4 • 8
*  p < 0*05, * *  p < o*oi f * * *  p < o*ooi
compared to phenformin-treated controls•
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although dichloroacetate causes hypoglycaemia in starved rats at a 
relatively low dose (2mmol/kg), larger or multiple doses do not 
cause proportionately greater hypoglycaemia* Thus at the doses used 
dichloroacetate appears to have an all-or-none rather than a graded 
effect on hlood glucose concentration, although the different routes 
of administration used make interpretation difficult* In the present 
study the response in streptozotocin-diahetic rats was clearly not 
dose-related since the reduction in hyperglycaemia was similar for 
each dose used, and the hlood glucose-lowering effect of dichloro­
acetate was already maximal at an oral dose of 1mmol/kg (Fig* 3*6)*
A similar reduction in the hyperglycaemia of streptozotocin-diahetic 
rats (15$) occurred after an intravenous infusion of sodium dichloro­
acetate (8mmol/kgt Blackshear et al** 1975a)t while larger decreases 
were obtained in alloxan-diabetic rats using diisopropylammonium 
dichloroacetate (l*7nimol/kg i*p*, 60$ decrease, Lorini and Ciman, 
19^2; 1*7mmol/kg i*p*, 35$ decrease, Stacpoole and Felts, 1970)» 
Decreases in the blood glucose concentrations of streptozotocin- 
diahetic rats have also been obtained using small oral doses of 
sodium dichloroacetate given subacutely (0*7mmol/kg/d for 7d,
Eichner et al•, 1974? 1 mmol/kg/d for 7d, Anderson, 1974)* The 
hyperglycaemia of human maturity-onset diabetics was similarly re­
duced by oral administration of dichloroacetate (5-27mmol/d for Jdf 
28$ decrease, Stacpoole et al., 1976)* It is clear, therefore, that 
dichloroacetate can act as an effective antidiabetic agent in both 
animals and humans*
Although the liver glycogen content of starved rats was very 
low, dichloroacetate caused a decrease at each time-point (Fig* 3*1 )• 
The action of sodium dichloroacetate on liver glycogen does not 
appear to have been studied previously, although the diisopropyl—
ammonium salt had no effect in starved rats (Cascio, 1958)* Since a 
fall in hepatic glycogen would be expected to increase blood glucose 
concentration, while the reverse was found, it is possible that the 
decrease was an indirect effect due to increased glycogenolysis con­
sequent upon decreased glycaemia. Incubation of hepatocytes isolated 
from starved rats with dichloroacetate did not change the rate of 
glycogen synthesis from lactate or fructose (Stacpoole,1977), again 
suggesting an action on glycogenolysis. Diisopropylammonium dich­
loroacetate (l.7mmo2/fcg'4«P«) not change the liver glycogen 
contents of alloxan-diabetic rats (Lorini and Ciman, 1962); similarly 
no consistent response was found in the present study using sodium 
dichloroacetate and streptozotocin-diabetic rats (Fig. 3.6).
Dichloroacetate given orally caused reductions in the blood con­
centrations of the three main gluconeogenic precursors - lactate, 
pyruvate and alanine - in starved and diabetic rats (Figs. 3«2, 3*6 
and 3*7)r in agreement with previous studies that used other routes 
of administration. In starved rats comparatively large falls in 
blood lactate concentration were obtained (8mmol/kg i.v., 50$ decrease 
Blackshear et al.» 1974, 3mmol/kg i.p*, 75$ decrease, White house et al 
1974; ? mmol/kg i.p., 35$ decrease, Goodman et al.. 1978) while in 
streptozotocin-diabetic animals results were inconsistent, with an 
intravenous load of 8mmol/kg having little effect but one of 4mmol/kg 
causing a 45$ decrease in lactataemia (Blackshear et al., 1975a). 
Dichloroacetate, however, clearly reduced the blood lactate concen­
tration of human maturity-onset diabetics (5-27mmol/kg p.o. for 7<1,
80$ decrease, Stacpoole et al., 1976). Decreases in blood pyruvate 
concentration of a similar magnitude to those found in the present 
study were obtained in starved rats (8mmol/kg i.v., 35$ decrease, 
Blackshear et al., 1974) although little or no change was found in
streptozotocin-diabetic rats (4 and 8mmol/kg i.v., Blackshear et al., 
1975^). Dichloroacetate caused dose-related decreases in hlood 
alanine concentrations in streptozotocin-diahetic rats (Fig. 3.7)» 
and similar fall£< have been noted previously in diabetic rats 
(4mmol/kg i.v., 60$ decrease, Blackshear et al., 1975a) and humans 
(20-27nimol/d p.o. for 7&, 80$ decrease, Stacpoole et al., 1978).
Blood acetoacetate concentrations were consistently and greatly 
raised following oral administration of dichloroacetate to starved 
rats (Fig. 3.3), in agreement with previous findings (8mmol/^€ i-v.,
75$ increase, Blackshear et al., 1974? 2mmol/kg i.p., 125$ increase, 
Goodman et al., 1978). Blood 3-hydroxyhutyrate concentrations, 
however, were not significantly elevated in the present study (Fig.
3.3), although increases of 80$ and 7C$ were obtained previously 
(Blackshear et al.. 1974? Goodman et al., 1978). The hlood acetoace­
tate concentrations of streptozotocin-diahetic rats were increased 
following oral administration of dichloroacetate, with 3-hydroxybuty- 
rate concentrations being unchanged or even decreased (Fig. 3*7)t 
contrast to the marked hypoketonaemia obtained previously (4mmol/kg i.v., 
acetoacetate 35$ decrease, 3-hydroxyhutyrate 40$ decrease, Blackshear 
et al.. 1975a). In human maturity-onset diabetics, however, the total 
plasma ketone body concentration was increased by 70$ following sub­
acute administration of dichloroacetate, with the concentrations of 
/
both acetoacetate and 3-hydroxybu±yrate increasing (Stacpoole.et al., 
1978). Thus the response of the blood ketone body concentration to 
dichloroacetate seems to vary with the metabolic state of the animal 
used and also with the species, human diabetics reacting somewhat 
differently to diabetic rats.
One common mechanism of the hypoglycaemic, hypolactataemic and 
hyperketonaemic actions of dichloroacetate appears to be the activation
of pyruvate dehydrogenase in the peripheral tissues following 
inhibition of pyruvate dehydrogenase kinase (Whitehouse and Randle,
1973 ; Whitehouse et al., 1974)* This may not be the only mechanism, 
however, since there is not always complete correlation between acti­
vation of pyruvate dehydrogenase by dichloroacetate and a decrease in 
gluconeogenesis (Harris and Crabb, 1973? Lacey and Randle, 1978)* In 
the present study dichloroacetate caused activation of pyruvate dehy­
drogenase in the heart, liver and skeletal muscle though not in the 
kidney of starved rats (Figs. 3.4 and 3.5)* while in a previous study 
large increases in activity were found in the heart (2,700$), kidney 
(170$) and epididymal adipose tissue (10C$), with smaller increases in 
liver (35$) and skeletal muscle (70$) of starved rats (tfhitehouse et 
al.« 1974)* In streptozotocin-diabetic rats increases in the activity 
of pyruvate dehydrogenase were found in liver, heart and kidney (Fig. 
3.8). Activation of pyruvate dehydrogenase in the peripheral tissues 
would lead to decreased release and even uptake of the gluconeogenic 
precursors lactate, pyruvate and alanine, so that their blood concen­
trations would fall and gluconeogenesis in the liver would be depressed 
Extraction of ketone bodies by the peripheral tissues would be expected 
to decrease since one of the enzymes involved in their utilization,
3-oxoacyl-coenzyme A thiolase, shares with pyruvate dehydrogenase a 
requirement for coenzyme A (McAllister et al.. 1973). Thus the acti­
vation of pyruvate dehydrogenase seen in both starved and diabetic 
animals can account for changes apparent in the blood concentrations of 
glucose, lactate, pyruvate, alanine and acetoacetate, although the 
reason why 3-hydroxybutyrate was not elevated is unclear. It may be ' 
that the liver is releasing to the blood most of its ketone body output 
as acetoacetate rather than as a mixture of 3-hydroxybutyrate and ' 
acetoacetate, possibly due to inhibition of the 3-hydroxybutyrate
dehydrogenase reaction.,,.
Since mitochondrial M D +/KADH ratios (see 3.3) were calculated 
using the blood concentrations of lactate, pyruvate, 3-hydroxybutyrate 
and acetoacetate it must be assumed that these metabolites are in 
equilibrium across cell and mitochondrial membranes if the values 
are to have any meaning. Although this is unlikely to be true for 
all tissues (Cohen and Woods, 1976), the change in the mitochondrial 
ratio in the absence of any effect on the cytosolic ratio suggests 
that dichloroacetate is acting primarily in the mitochondrion, the 
site of pyruvate dehydrogenase activity. Activation of pyruvate 
dehydrogenase would, however, tend to decrease the ratio,
so that there may be two or more pools of nicotinamide adenine 
dinucleotides in the mitochondrion, one associated with pyruvate 
dehydrogenase and another with 3-hydroxybutyrate dehydrogenase.
The finding that pretreatment with dichloroacetate did not con­
sistently lead to blood glucose concentrations significantly lower 
than those obtained with phenformin alone (Tables 3.1 and 3.2) is in 
contrast to some previous work in which dichloroacetate was found to 
enhance the hypoglycaemic effect of phenformin in starved rats 
(Holloway and Alberti, 1975)• These workers found that phenformin 
alone caused only a 5$ decrease in glycaemia, so that the large 
decrease in blood glucose obtained when dichloroacetate was given 
with phenformin was presumably due to the dichloroacetate exerting 
its own hypoglycaemic effect. In subsequent work dichloroacetate 
(5mmol/kg i.v.) given with phenformin (0.5mmol/kg i.v.) caused the 
blood glucose concentration of starved rats to fall to 1.8mM, com­
pared with 2.0mM when only phenformin was infused (Holloway and 
Alberti, 1976). In the present work using streptozotocin-diabetic 
rats phenformin and dichloroacetate each produced relatively large
hypoglycaemic responses which were not additive, consistent with previous 
findings in the streptozotocin-diabetic rat in which phenformin and dich— 
loroacetate were administered alone or in combination (Man and ./Alberti, 
1977)* After 28d the blood glucose concentrations in the three groups 
were in the range 5-8.5nM» compared with levels before treatment of 
18-24.5eM* Similarly, in human maturity-onset diabetics given dich­
loroacetate in combination with the biguanide buformin blood glucose 
concentrations at the end of the trial were similar to those found in 
the same patients when receiving buformin alone (Standi et al., 1977).
It is possible that phenformin and dichloroacetate act on the same 
metabolic pathway. Once this pathway is inhibited (or activated) 
maximally by one compound administration of the other cannot cause 
significant further inhibition, so that the blood glucose concentration 
is not further decreased.
The minimum molar ratio of dichloroacetate/phenformin of 8 required 
to abolish completely the hyperlactataemic response of streptozotocin- 
diabetic rats to phenformin (Table 3.2, Fig. 3*9) is similar to those 
deduced for previous studies using different routes of administration- 
approximate values ranging from 2 to 11 for starved and streptozotocin- 
diabetic rats (Holloway and Alberti, 1975? Holloway and Alberti, 1976? 
Alberti and Holloway, 1977? Kuhnle et al., 1977? Ifen and Alberti, 1977).
The large increases in blood 3-hydroxybutyrate concentration seen 
after administration of dichloroacetate to phenformin-pretreated rats 
(Table 3*2) are of the same magnitude as the increases found in starved 
rats given dichloroacetate (2mmol/kg i.v.) one:hour after an infusion 
of phenformin (0.42mmol/kg i.v.) - 113$ (Alberti and Holloway, 1977) 
and 175$ (Holloway and Alberti, 1977). In the present work neither 
phenformin nor dichloroacetate alone caused an increase in blood 3-hydro­
xybutyrate concentration, but dichloroacetate caused an increase in
blood acetoacetate and the calculated mitochondrial FAD^MADH ratio. 
It may be that phenformin acts to supply HADH to the appropriate 
mitochondrial pool, so that the 3-hydrorybutyrate dehydrogenase 
reaction proceeds and 3-hydro2ybutyrate is produced from acetoace­
tate and 2TAD3.
Dichloroacetamide acted similarly to dichloroacetate in that it 
could abolish the hyperlactataemia caused by phenformin in diabetic 
rats (Pig# 3»10). Its mechanism of action is uncertain, however, 
because unlike dichloroacetate dichloroacetamide did not inhibit 
pig heart pyruvate dehydrogenase kinase or*activate pyruvate dehy­
drogenase in rat heart mitochondria, although like dichloroacetate 
it activated pyruvate dehydrogenase in isolated rat diaphragm and 
fat pads (Whitehouse et al., 1974)*
CHAPTER 4 
STUDIES OH THE MECHA1TISM OP ACTIOIT 
OP PHEHFORMIH IH THE RAT
4*1 Introduction
Although the hypoglycaemic action of phenformin in man and in 
experimental animals has been recognised for many years the underlying 
biochemical mechanism for this effect, and for the hyperlactataemia 
that usually accompanies it, is still not known with certainty.
It is generally thought that phenformin is itself the pharmacolo­
gically active molecule rather than any metabolite (Quest et al.> 1980), 
although 4-hydroxyphenformin has been reported to be about 50$ as 
effective as phenformin in causing hypoglycaemia (Wick et al.. 1970)* 
Hydroxylation of aromatic compounds at the 4-position is inhibited by 
4-halosubstitution (Daly et al., 1968), so that 4-fluorophenformin should 
be pharmacologically more active than phenformin. The effects of 4-hydro- 
xyphenformin, 4-ethoxyphenformin and 4-fluorophenformin on blood glucose 
and lactate concentrations were compared with those of phenformin in 
diabetic rats in an attempt to confirm that phenformin is the active 
molecule and to assess the hypoglycaemic and hyperlactataemic activities 
of related compounds.
Phenformin inhibits intestinal transport of glucose (Kzmger et al., 
1970; Caspary and Creutzf eldty 19T1) * The ..effects of in vivo administra­
tion of phenformin on glucose absorption across jejunal sacs were deter­
mined in fed, starved and diabetic rats so that the importance of intes­
tinal effects to the overall hypoglycaemic action might be gauged.
The effects of phenformin on the ability of fed, starved and diabetic 
rats to handle an exogenous glucose load were determined so that any action 
of phenformin on pathways of glucose disposal might be elucidated. Further 
loading experiments using a variety of gluconeogenic percursors and tri­
carboxylic acid cycle intermediates were performed to try to find the 
locus of phenformin's biochemical action. Starved rats were used in 
these experiments since their blood glucose concentrations were the most
sensitive to small changes, being much lower than those of fed or dia­
betic animals »
A comparison of the effects of phenformin on the concentrations of 
key metabolites, including glucose, glycogen, pyruvate, lactate, ketone 
bodies, citrate, succinate and malate, in blood, liver and skeletal 
muscle was made in fed, starved and diabetic animals. Thus if the 
primary metabolic disturbance were located in the liver or muscle it 
might be identified; and differences in the effects of'phenformin in 
the different animal models might be correlated with differences in 
hypoglycaemic and hyperlactataemic activity.
4.2 Materials and methods
4.2.1 Chemicals
Sterling-Winthrop Research Laboratories, Fawdon, Newcastle donated 
4-hydroxyphenf ormin hydrochloride, 4-etharyphenf ormin dihydrochloride 
and 4-fluorophenformin dihydrochloride. Glycerol, D(-) fructose, 
sodium L-glutamate and trisodium citrate were supplied by British Drug 
Houses, Poole, Dorset and monosodium L-malate, disodium succinate and 
2-oxoglutaric acid were from Sigma Chemical Company Ltd., Poole, Dorset. 
Before use 2-oxoglutaric acid was brought to pH 6 using 2M sodium hydro­
xide. Enzymes and cofactors used in the determinations of citrate, 
glutamate, succinate, malate, DAD+, SADH, NADP+ and HADPH were supplied 
by Sigma. All other chemicals were obtained from Sigma or British Drug 
Houses or from the source specified in 2.2.1.
4.2.2 Materials
Autoanalyser cups prefilled with fluoride and oxalate were sup­
plied by Stayne Laboratories Ltd., Marlow, Buckinghamshire.
4*2.3 Animals
Adult male Wistar albino rats were used in all experiments. Some 
animals were starved or rendered diabetic and anaesthesia was induced
by sodium pentobarbitone as described in 2.3,3.
Administration of compounds
Phenformin hydrochloride, 4-hydroxyphenformin hydrochloride, 
4-ethoxyphenformin dihydrochloride and 4-fluorophenformin dihydro— 
chloride were dissolved in 0.154M saline before intraperitoneal 
injection, the pH of the solution being adjusted if necessary to 
6-6.5 using 1M sodium hydroxide. For a dose of 'x'mmol/kg, the con­
centration used was 0*5xM. For intraperitoneal glucose tolerance 
tests, the glucose (12.5M in distilled water, 8.3mmol/kg) was given 
to rats anaesthetised with sodium pentobarbitone while in the oral 
glucose tolerance test the same dose of a similar glucose solution 
was administered to anaesthetised animals. In experiments involving 
intraperitoneal administration of gluconeogenic precursors and tricar­
boxylic acid cycle intermediates, the compound was given at a dose of 
2mmol/kg and concentration of 1M dissolved in distilled water or 0.154M 
saline, except for fructose (0.5M, 1mmol/kg). In experiments using 
fluoride to inhibit glycolysis sodium fluoride (O.25M in 0.154M saline, 
0.5mmol/kg i.p.) was administered to unanaesthetised rats. The subse­
quent glucose load (20M in distilled water, 13.3mmol/kg i*P*) was given 
to animals anaesthetised with sodium pentobarbitone. Glycexyl tripal- 
mitate was administered at a dose of 2mmol/kg and concentration of 0.17M 
dissolved in corn oil.
Collection of blood and tissue samples
For serial samples blood . was collected from the tail as described 
in 2.3.3. For assay of tissue metabolites a large blood sample (about 
5ml) was drawn from the inferior vena cava and immediately expelled into 
an equal volume of ice-cold 0.7M perbhloric acid^except for a small 
aliquot (0.5ml) some of which (about 0.3ml) was preserved in a fluoride- 
oxalate cup and used to estimate glucose, the remainder (0.2ml) being
deproteinised with 0.7M perchloric acid (0.4ml) for use in the deter­
mination of lactate. A portion of the large lobe of the liver was 
rapidly removed and squeezed between the plates of tongs cooled to 
the temperature of liquid nitrogen, and a sample of femoral muscle 
was treated similarly. Liver and skeletal muscle samples were kept in 
liquid nitrogen until extraction of metabolites into perchloric acid. 
After removal of aliquots for glycogen assay liver and muscle powders, 
prepared by pulverising the tissue under liquid nitrogen in a mortar 
and pestle, were subjected to a double extraction with perchloric acid— 
the powder was homogenised in ice-cold 0.6M perchloric acid (5ml/g 
tissue) using a Tri-R Stir-R Potter-type homogeniser, the homogenate 
was centrifuged (MSE Minor, 4,000 rpm for 5min), the supernatant was 
decanted and 0.3M perchloric acid (2ml/g tissue) was added to the 
sediment. After vigorous shaking the mixture was centrifuged again, 
the supernatants were combined and made up to a concentration of 8ml/g 
tissue using distilled water. The acid extract was neutralized to pH
6-8 with 215 potassium hydroxide and stored at -15°C.
Everted jejunal sacs were used to estimate glucose absorption from 
the intestine using a technique based on that of Wilson and Wiseman 
(1954)* The rat was killed by cervical dislocation, the abdomen rapidly 
opened and a small (1ml) blood sample was immediately withdrawn from the 
inferior vena cava and used for lactate and glucose assays. A 14-cm 
length of jejunum was obtained by unfolding the intestines and cutting 
at 10cm and 24cm from the base of the stomach and after cutting into two 
7cm portions it was immersed in bicarbonate-saline (0.15415 solutions of 
sodium chloride, potassium chloride, dipotassium hydrogen phosphate, mag­
nesium sulphate and sodium bicarbonate mixed in the ratio 100 : 4 • 1 s 1 
s 21 by volume, pH 7*5* Krebs and Henseleit, 1932) ia a Petri dish.
After washing out the contents of the lumen by running through bicar-
bonate-saline, the segment was everted on a thin glass rod. One end of
the everted segment was tied off with thread and 0.6pl of bicarbonate-
saline containing glucose was introduced via a blunt needle through
a loose ligature at the other end. The sac was tied off and placed in 
15ml glucose solution (bicarbonate-saline containing 5*6mM glucose) pre­
viously warmed to 37°G and gassed for about 15min with 95$ Og ^$ 
a conical flask. The flask was incubated at 37°C with shaking for
1h, the external glucose solution being continuously gassed with 95$ Og 
5$ COg* At the end of the incubation^ sac (serosal) and flask (mucosal) 
solutions were assayed for glucose and the segment was cut at the liga­
tures,-blolrted'dry and weighed to obtain the effective fresh tissue 
weight. Mucosal absorption of glucose was calculated from values of the 
change in glucose concentration (mM) in the flask and the fresh tissue 
weight (mg), using
mucosal glucose * / \  [glucose] x .1 5  nmols glucose/h/mg fresh wt • 
absorption tissue wt.
4.2.4 Assay methods
Glucose, glycogen, lactate, pyruvate, alanine, acetoacetate and 3-hydro- 
xybutyra-fre
Glucose, lactate, pyruvate, alanine and the ketone bodies were 
determined in blood using the methods described in 2.2.5. Glycogen was 
measured by the method of Pfleiderer (1963). The liver or muscle sample 
was powdered in a mortar and pestle under liquid nitrogen and a portion 
(100 or 200mg for liver, 150-400mg for muscle) was weighed into 5*4M 
potassium hydroxide solution (2ml). The mixture was heated in a bath 
of boiling water for 15min then cooled briefly before the addition of 
3.5®1 - ethanol. After cooling to room temperature, the precipitate con­
taining the glycogen was obtained by centrifugation and hydrolysed to 
glucose by heating with 1M sulphuric acid (2ml) in a bath of boiling water
for 2h. The solution was cooled to room temperature, neutralized with 
1M sodium hydroxide and the glucose concentration of a suitable dilution - 
was estimated using the method of Morley et al (1968). Lactate, pyruvate, 
acetoacetate, alanine and 3-hydroxybutyrate concentrations were determined 
in neutralized tissue extracts by the same methods as used for blood. 
Citrate, glutamate. succinate and malate
Citrate was determined in blood by the spectrophotometric method of 
Dagley (19T4) in which 0.5ml sample (neutralized perchloric acid super­
natant stored frozen) was mixed with 2.5ml buffer (0.1M triethanolaraine 
containing 0.2mM zinc chloride| pH 7*6), 0.05ml UADH solution (lOmM in 
distilled water) and 0.02ml of a mixture of lactate dehydrogenase 
(1700 u/ml)and malate dehydrogenase (2,000 u/ml)in 3.2M ammonium sulphate 
solution. After leaving for 15min and reading the extinction at 340nm 
the solution was mixed with 0.02ml citrate lyase (40 u/mi) in distilled 
water) and left at room temperature for 1h. The blood citrate concen­
tration was-calculated^, from the .aquation
blood citrate concentration (mM) = A  E.j^ x 1.00 x F  
where F, the dilution factor, was calculated for each sample from values 
of blood, acid supernatant, and neutralised:supernatant vvblumes.
Citrate was determined in tissue extracts by the fluorimetric 
method of Passonneau and Brown (1974) in which 0.4 or 0*5ml sample 
(neutralized perchloric acid supernatantr s bored frozen) was mixed with 
3 or 4ml of a reagent mixture comprising NADH , magnesium chloride
(0.2mM), EDTA (0.1mM) and malate dehydrogenase (200U/ml) in 50mM Tris 
buffer, pH 8.0. After recording a steady fluorescence with excitation 
at 360m and emission at 460nm, 0.02ml citrate lyase (4CU/ml in 50mM 
triethanolamine buffer, pH 7*4, containing 30jtM zinc chloride and 0.5M 
ammonium sulphate) was added and the change in fluorescence was recorded 
using a Perkin-Elmer MFF-3 fluorescence spectrophotometer connected to a
Hitachi Recorder QPD33. Trisodium citrate standards (23-91fiM) were 
processed similarly and used to calibrate the assay.
Glutamate was measured in blood and tissue extracts using the 
method of Bernt and Bergmeyer (1974) in which 0.5ml sample (neutra­
lized perchloric acid supernatant stored frozen) was mixed with 1ml 
buffer (0.5M glycine and 0.4M hydrazine hydrate; pH 9*0), 0.05ml ADP 
solution (33*5mM in distilled water) and 0.1ml NAB+ solution (27mM ... 
in distilled water). The change in extinction after the addition of 
0.02ml glutamate dehydrogenase (500u/ml in 5*4M glycerol) was recorded 
at 340nm. Sodium L-glutamate standards (20-500^jM) were processed 
similarly and used to calibrate the assay.
Succinate was determined in tissue extracts by a modification of 
the method of Williamson (1974) in which 0.25ml sample (neutralized 
perchloric acid supernatant, stored frozen) was mixed with 2.0ml buffer 
(50mM triethanqlamine containing 10mM magnesium chloride and 5mM EBTA ; 
pH 7**4), 0.2ml HADH solution (2*4mM in triethanolamine buffer) and 
0.05ml coenzyme mixture (5mM coenzyme A ; 10mM inosine 5-^niphosphate ; 
50mM phosphoenolpyruvate). The extinction was recorded at 340nm after 
the addition of 0.01ml of a mixture in distilled water of lactate dehy­
drogenase (860 V/wl)and pyruvate kinase (400 u/ml)until a steady value 
was' obtained, when 0.01ml succinate thiokinase (l6u/ml in 3.2M ammonium 
sulphate) was added. The change in extinction at 340nm was recorded 
and compared to those of disodium succinate standards (0.2 - 1.0mM) 
treated similarly.
Malate was measured by a modification of the method of Goldberg 
and Passonneau (1974) in which 0.05 or 0.1ml sample (neutralized per­
chloric acid supernatant stored frozen) was mixed with 4 or 2.5ml of a 
reagent mixture comprising EBTA (0.2mM) and NAD+ (60juM) in 0.1M hydra­
zine hydrate buffer, pH 9*0* After recording a steady fluorescence
with excitation at 360nm and emission at 460nm, 0.02ml malate dehydro­
genase (1,000 u/ml in 0.02M Tris buffer, pH 8.0) was added and the 
change in fluorescence was recorded. Sodium L-malate standards 
(0.1-0.2mM) were used to calibrate the assay.
NAP*, MDH. NADP* and NADPH
The tissue concentrations of the nicotinamide-adenine dinucleotides
were determined using the methods of Klingenberg (1974) in which an acid
+ +
extract was prepared for the measurement of NAP and NADP and an alka­
line extract for the determination of NADH and NADPH. The acid extract was 
prepared by mixing 0.5g tissue, pulverised under liquid nitrogen using a 
mortar and pestle, with ice-cold 0.6M perchloric acid (2.5ml). After 
centrifugation (MSE Minor, 4»000rpm for 5min), 2ml of the supernatant was 
mixed with 0.4ml dipotassium hydrogen phosphate (1M) and brought to pH
7-3 with 2M potassium hydroxide solution. In the assay of NAD* 0.5ml 
neutralized extract was mixed with 0.5ml buffer (0.1M sodium pyrophos­
phate and 45mM semicarbazide hydrochloride, pH 8.8) and 0.05ml absolute 
ethanol. The change in extinction at 34Q*im was recorded after the addi­
tion of 0.01ml alcohol dehydrogenase (340 u/ml in 3.2M ammonium sulphate).
+
For the assay of NADP , 1.0ml neutralized extract was mixed with 0.005ml 
magnesium sulphate (1M in distilled water) and 0.025ml disodium glucose- 
6-phosphate (0.2M in distilled water) and the change in extinction at 
340nm was recorded after the addition of 0.01ml glucose-6-phosphate 
dehydrogenase (325 u/ml in 3.2M ammonium sulphate). .
The alkaline extract was prepared by mixing 0.5g tissue powder with 
4ml alcoholic potassium hydroxide solution (0.5M in 50$ (v/v) ethanol) in 
a tube kept at -15°C using an ice-salt mixture. The alkaline mixture was 
warmed for 5min in a water-bath at 90°0 , then cooled rapidly in an ice- 
bath. After neutralization to pH 7-8 with 3-4ml buffer (0.5M triethan- 
olamine hydrochloride; 0.4M potassium dihydrogen phosphate; 0.1M dipo-
tassium hydrogen phosphate) the solution was allowed to stand for about
10min to allow flocculation of denatured protein, which was then removed -
by centrifugation (MSE Mistral 6L, 3,000 rpm for 20min at 4°C). The
supernatant was kept cold and used as soon as possible for the assays
of-NASH and NADPH* The neutralized extract (3ml) was mixed with 0.1ml
substrate mixture comprising 2QmM dihydroxyacetone phosphate, 0.1M
2-oxoglutaric acid and 0.2M ammonium chloride. The change in extinction
at 340nm was recorded after the addition of 0.01ml glycerolphosphate
dehydrogenase (l65U/ml in 2M ammonium sulphate), indicating the NADH
concentration, and the further extinction change after adding 0.01ml
glutamate dehydrogenase (lOCXj/ml in 2M ammonium sulphate) indicated the
NADPH concentration. The concentration of each dinucleotide in the
final, neutralized solution ■
A E  ;. assay volume
d.v £.. sample volume
where A E  * change in extinction at 340nm, d * -light path length (1cm)
2 /
and £ =« extinction coefficient of NADH and NADPH at 340nm (6.22 cm / 
mole). In calculating the tissue concentration of each dinucleotide 
the dilutions of the tissue in the extraction and of the extract on 
neutralization were taken into account by using appropriate dilution 
factors.
Analysis of data
The methods described in 2.2*5 were used to assess the statistical 
significance of differences found between control and test groups. In 
the figures points or bars represent the group mean with the standard 
error of the mean being shown by vertical lines.
4*3 Results
4-3.1 Comparison of the hypoglycaemic and hyperlactataemic activities 
of 4-hydroxyphenformin, 4-ethoxyphenformin, 4-fluorophenformin and
phenformin
The effect of 4-^cfroxyphenformin on the blood glucose concentra­
tion of diabetic rats was very similar to that seen in saline-injected 
control animals, being a gradual decrease followed by a return towards 
the initial blood glucose concentration (Fig. Phenformin-treated
rats tended to have lower blood glucose concentrations and 4-ethoxyphen;— . 
formin-treated animals higher glucose concentrations than those seen in 
control animals, although the differences were not statistically signi­
ficant. Phenformin caused hyperlactataemia, with the blood lactate con­
centration reaching a peak 2h after administration of the biguanide, but 
the effects of 4-hydroxyphenformin and 4-ethoxyphenformin were indistin­
guishable from that seen in saline-injected controls, an initial sharp 
fall leading to a relatively stable blood lactate concentration (Fig. 4«2)
Beither 4-fluorophenformin nor phenformin caused changes in the blood 
glucose concentration of diabetic rats that were significantly different 
from those seen in control animals, although blood glucose concentrations 
were generally higher in 4-f luorophenformin-treated animals than in con­
trols and lower in those receiving phenformin (Fig. 4*3 )• Phenformin, 
however, caused a pronounced hyperlactataemia, reaching a peak 2h after 
its administration, that was not apparent in control animals (Fig. 4*4)*
In contrast 4-fluorophenformin caused hyperlactataemia of similar magni­
tude but in which the blood lactate concentration remained elevated for 
the 5h duration of the experiment. The blood lactate concentration of 
saline-injected control rats remained low and relatively stable.
4*3»2 Effects of phenformin on the handling of glucose loads
Pretreatment of fed rats with phenformin lowered the glucose toler­
ance curve but since this effect was mainly due to an initial depression 
in the blood glucose concentration, before administration of the glucose 
load, the tolerance was only slightly changed and the area under the curve
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bounded by the initial blood glucose concentration for phenformin- 
treated rats was 75$ of that for control animals (Pig* 4«5)* Similarly, ‘ 
blood lactate concentrations were significantly higher in animals re­
ceiving phenformin, but most of the difference was apparent before 
administration of the glucose load, although there was a gradual 
increase in blood lactate concentration after glucose loading* Com­
parison of areas between the two curves for each of blood glucose and 
blood lactate over the duration of the experiment indicated that 94$ 
of the excess lactate produced in rats receiving phenformin could be 
accounted for by the difference in areas between the blood glucose 
curves, with one unit area between the glucose curves being equivalent 
to two units of area between the lactate curves.
Pretreatment of starved rats with phenformin greatly increased their 
tolerance to an intraperitoneal glucose load (Pig* 4«6), decreasing the 
peak blood glucose concentration from the control value of 8*5 t 0*5mM to 
3*9-0«4bjM* The area under the curve for rats receiving phenformin, 
using the initial blood glucose concentration as the lower boundary, was 
only 13$ of that for control animals* Comparison of areas between the two 
curves for each of blood glucose and blood lactate indicated that all of 
the extra,, lactate found in rats receiving phenformin could be accounted 
for by 77$ of the difference found in blood glucose over the duration of 
the experiment*
Although there was an indication that the glucose tolerance of strep- 
tozotocin-diabetic rats was impaired following administration of phenformin 
(Pig* 4*7)» the glucose concentration of blood sampled before glucose 
loading was higher in the phenformin group and the differences between 
the points on the tolerance curves were rarely statistically significant* 
Despite its apparent inability to lower the initial blood glucose concen­
tration phenformin caused a marked increase in the initial blood lactate
administration of phenformin and an intraperitoneal glucose load
BLOOD GLUCOSE (mM>
4 -
BLOOD LACTATE (mM)
L
0 0-5 1 1-5 2 %
TIME AFTER ADMHTISTRATIOU OF GLUCOSE (h)
3
Fed rats (220-275g) were given phenformin (0.5mmol/kg i.p.) or saline and 0.8h 
later were anaesthetised with sodium pentobarbitone. At 1h a blood sample was 
taken from the tail and a glucose load (8*3mmol/kg i.p.) immediately administered.
A Phenformin (n=3) A Saline (n»5)
* P < 0.05, ** P < 0.01, *** P <0.001 compared with control.
Fig. 4*6 Blood glucose and lactate concentrations in
starved rats following administration of phenformin and
an intraperitoneal glucose load '
Starved rats (l55“225g) were given phenformin (0.5mmol/kg i.p.) 
or a similar volume of 0.154M saline. After 0.8h the animals 
were anaesthetised with sodium pentobarbitone and at 1h an 
intraperitoneal glucose load (8.3mmol/kg) was given. Blood 
samples were taken from the tail at intervals for 3h after 
administration of glucose.
■ Phenformin (n=6)
□ Saline (n=6)
** P < 0.01 r *** P <, 0.001 compared with control
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Pig. 4.7 Blood glucose and lactate concentrations in strep-
tozotocin-diabetic rats following administration of phenformin
and an int raperi t one,al: glucose load
Rats (205-235g) were rendered diabetic by the intravenous 
administration of streptozotocin and about 23h later were given 
phenformin (Q.5mmol/kg i.p.) or a similar volume of O.154M saline. 
After 0.8h the animals were anaesthetised with sodium pentobar­
bitone and at 1h a blood sample was taken from the tail. A glucose 
load (8.3mmol/kg i.p.) was immediately given and further blood 
samples taken at intervals for 3h.
■ Phenformin (n*3)
□ Saline (n*3)
* P< 0.05, ** P < 0.011 *** P < 0.001
compared with control.
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concentration. The hyperlactataemia was maintained throughout the 
course of the experiment•
Phenformin greatly increased the tolerance of starved rats to an 
oral glucose load, simultaneously producing marked hyperlactataemia 
(Fig. 4.8). Since the "blood glucose concentrations of starved, pento­
barbitone-anaesthetised control rats are normally in the range 3-4mM» 
not only did phenformin abolish the large increase in glycaemia seen in 
control animals, after the glucose load but also exerted a marked hypo- 
glycaemic action, so that blood glucose concentrations fell sharply to 
very low levels. If a blood glucose concentration before glucose loading 
of 3*5.mM is assumed, comparison of the area between this limit and the 
glucose curve for phenformin-treated animals and the area between the 
two lactate curves indicated that fully 7&fo of the excess lactate pro­
duced by phenformin can be accounted for by its hypoglycaemic action.
If the arbitrary limit chosen is 4niM, the value is 102$. Thus the con­
tribution of the glucose from the oral load to the hyperlactataemia seen 
in phenformin-treated animals may be minimal.
Administration of sodium fluoride to starved rats impaired their 
tolerance to an intraperitoneal glucose load, the peak blood glucose 
concentration being significantly higher and the area under the curve 
greater than those in animals receiving only saline (Fig* 4*9)» Con­
versely, phenformin improved glucose tolerance both alone, when compared 
to saline-treated controls, and in combination with fluoride, when com­
pared with animals receiving fluoride and saline. The ratios of the 
areas under the curves, using the initial blood glucose concentrations 
as the lower boundaries, were fluoride 1.82, fluoride with phenformin
1.03 and phenformin 0.66, compared with 1.00 for saline. Phenformin, 
alone or in combination with fluoride, caused pronounced hyperlactat­
aemia in these animals, and blood lactate concentrations of rats receiving
Fig. 4*8 Blood glucose and, lactate concentrations in starved
rats following administration of phenformin and an oral glucose
load
Starved rats (290-325g) were given phenformin (0.5mmol/kg i.p.) 
or a similar volume of 0*1541*1 saline. After 1h an oral glucose 
load (8.3mmol/kg) was administered and 0.33h later the animals 
were anaesthetised with sodium pentobarbitone. Blood samples 
were taken from the tail at 0.5h after administration of the 
glucose and at intervals for a further 2*5h.
■ Phenformin (n»3)
□ Saline (n*3)
* P  < 0.05, ** P < 0.01, *** P < 0.001
compared with control.
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Pig. 4*9 Blood glucose and lactate concentrations in starved,
glucoser-loadcd rats following intraperitoneal administration of 
phenformin with or without fluoride
Starved rats (l55~260g) were given phenformin (0.5mmol/kg i.p.) 
and/or 0.154M saline and/or sodium fluoride (0.5mmol/kg i.p.). 
After 0.8h the animals were anaesthetised with sodium pento­
barbitone and at 1h an intraperitoneal glucose load ;(-13mmol/kg) 
was given. Blood samples were taken from the tail at intervals 
for 3h after glucose administration,
A Pluoride + saline (^*4)
• Phenformin + saline (n=*4)
A Pluoride + phenformin (a*^)
O Saline (n=3)
* P < 0.05, ** P < 0.01, *** P < 0.001
compared with group receiving only saline.
The mean blood glucose concentration of the phenformin group 
was significantly lower than that of the fluoride + phenformin 
group at 0.5h ( P < 0.01), 1h ( P < 0.01) and I.5& ( P_ < 0.05) 
after administration of glucose.
14 r
12
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BLOOD LACTATE (mM)
1 1*5 2
TIME AFTER ADMHTISTRATI01T OF GLUCOSE (h)
CH5
fluoride alone were indistinguishable from those of controls*
4*3*3 Effects of gluconeogenic precursors on phenformin-induced hypo- 
glycaemia and hyperlactataemia
When phenformin was administered before the pentobarbitone anaes­
thetic. to starved rats also receiving saline it caused a marked hypo- 
glycaemia, blood glucose concentrations continuing to fall throughout 
the 3h of the experiment. (Fig* 4*10)* The blood lactate concentrations 
of these animals were raised (Fig. 4«11)* Thus the usual action of phen­
formin in initially-mnanaesthetised, starved rats was to cause pronounced 
hypoglycaemia and hyperlactataemia, and in further experiments various 
precursors of gluconeogenesis were administered in attempts to prevent 
these effects*
All of these compounds (fructose, glycerol, lactate, citrate, 2-oxo- 
glutarate, succinate and malate) were apparently gluconeogenic in that 
after their administration the blood glucose concentrations of control 
animals rose sharply (Fig. 4# 10)* In each case phenformin lowered the 
initial bleed glucose concentration at the zero time point, before 
administration of the load, often to a statistically significant extent. 
Similarly, phenformin always raised the initial blood lactate concentra­
tion (Fig. 4*11)• Several of the gluconeogenic loads - fructose, glycerol 
succinate and malate - prevented the development of the marked hypogly­
caemia normally caused by phenformin in saline-loaded controls, while 
others - lactate, 2-oxoglutarate and particularly citrate - could not 
interfere with* this pharmacological action of phenformin. Similarly, 
several of the compounds - fructose, glycerol and succinate - prevented 
the development of the pronounced hyperlactataemia usually obtained with 
phenformin, while with lactate, citrate, 2-oxoglutarate and to a lesser 
extent malate, the increase in the blood lactate concentration above the 
initial level was similar to or greater than that found in animals re-
Fig. 4-.10 Blood glucose concentrations in starved rats following
intraperitoneal administration of -phenformin and a gluconeogenic
load
Starved rats (l60-280g) were given phenformin (0.5mmol/kg i.p.) 
or a similar volume of 0.154M saline. After 0.8h the animals 
were anaesthetised with sodium pentobarbitone and at 1h a blood 
sample was taken from the tail. A loading dose of a gluconeo­
genic compound (2mmol/kg i.p. except fructose - 1mmol/kg i.p.) 
was immediately administered and further blood samples were 
collected at intervals for 3h.
load
saline
fructose
glycerol
lactate
citrate
2-oxoglutarat e
succinate
malate
no. of animals 
phenformin a  saline a
4 4
3 4
3 3
6 7
6 6
6 7
7 6
7 6
* F < 0.05, ** P < 0.01, *** P < 0.001
compared with control.
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ceiving phenformin and saline. The ratios of the areas under the lactate 
curves for animals receiving phenformin, using the initial blood lactate. 
concentrations as the lower boundaries, were saline 1.00, fructose 0.19» 
glycerol - 0.43, lactate 0.90, citrate 1.80, 2-oxoglutarate 1.12, 
succinate 0,2J and malate 0.59*
Administration of disodium succinate at the same time as phenformin 
lessened the hypoglycaemic and hyperlactataemic effects of the biguanide, 
often to a statistically significant extent (Fig. 4*12), so that the blood 
lactate concentrations of rats receiving phenformin and succinate were 
closer to control levels than to those in animals receiving phenformin 
and saline. Pretreatment with glyceryl tripalmitate caused a similar, 
though smaller, decrease in phenformin-induced hyperlactataemia, but had 
little effect on the hypoglycaemia, if anything causing a further lowering
of the blood glucose concentration (Fig. 4«13)«
4*3.4 Comparison of blood, liver and muscle metabolite concentrations in 
fed, starved and streptozotocin-diabetic rats after phenformin treatment 
Phenformin lowered the blood glucose concentration of fed and strep— 
tozotocin-diabetic rats, the decrease seen in starved animals not being 
statistically significant (Fig. 4*14)* Large decreases in the\hepatic 
glycogen contents of fed and diabetic rats were also apparent, with no 
change in the very low levels found in starved rats. The control levels
of muscle glycogen showed much less variation between the different
animal models than did those for liver glycogen, and phenformin did not 
cause any significant changes (Fig. 4*14)*
Blood and tissue pyruvate concentrations were largely unchanged 
following administration of phenformin (Fig. 4*15) t although an increase 
in blood pyruvate was apparent in fed rats. Conversely, the liver pyru­
vate content of fed rats was decreased by phenformin.
Phenformin raised the blood lactate concentrations of fed, starved
BLOOD GLUCOSE (mM) 
5 r
4 -
2 -
f
11-
BLOOD LACTATE (mM) 
4
t*J
0*-
I_
0 1 1*5 2 2-5 3
TIME AFTER ADMnTISTRATIOR OF PHENFORMUT (h)
Starved rats (l35“225g) were given phenformin (0.5mmol/kg i.p*) or saline* 
Disodium succinate (2mmol/kg i*p*) was administered at the same time and 0.8h 
later the animals were anaesthetised with sodium pentobarbitone* At 1h and at 
intervals until 4b- blood was sampled from the tail.
• Phenformin + succinate (n=6)
* Phenformin + saline (n=*5)
A  Saline + succinate (n-3)
* P K 0*05, ** P ( 0*01, *■** P <( 0.001 compared with control. 
t P K tt P ^ 0.01, ttt P ^ 0.001 compared with phenformin + saline.
~'JL±UJ*1+±° vac* uxun ui yxjidiJ. ua mxii
BLOOD GLUCOSE (mM)
21-
BLOOD LACTATE (mM) 
4 r
w_ t/_ w.^ n \w
0 1 2 / x 3
TIME AFTER ADMINISTRATION OF PHENFORMIN (h)
Fed rats (l60-l80g) were given glyceryl tripalmitate (2mmo3/kS P»°0 or 
distilled water and 2h or 4h later phenformin (O*5mmo3/kg i*P*) or saline was 
administered* After 0.8h the animals were anaesthetised with sodium pentobar­
bitone and at 1, 2 and 3h blood was sampled from the tail.
■ Glyceryl tripalmitate + phenformin (n=*5)
A Distilled water + phenformin (n^)
□ Glyceryl tripalmitate + saline (n-3)
A  Distilled water + saline (n*3)
* P ^ 0.05, **• P < 0.01, *** p ^ 0.001 compared with control.
t* P ^ 0.05 compared with glyceryl tripalmitate + phenformin.
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and diabetic rats, although the increase seen in starved animals was 
not statistically significant (Pig* 4*16). There was little corres­
ponding change in the tissue levels, apart from an increase in the 
lactate content of muscle from diabetic rats.
Although- administration of phenformin tended to increase blood 
and tissue concentrations of alanine, only an increase in liver alanine 
in fed rats was statistically significant (Pig* 4*1?)*
Phenformin did not cause any significant changes in blood and
tissue acetoacetate concentrations (Pig* 4*18), although it raised
blood and tissue 3-hydroxybutyrate concentrations, particularly in fed
and diabetic animals (Pig* 4*19)* The liver and muscle 3-hydroxybuty-
rate/acetoacetate ratios were calculated from individual metabolite
concentrations and the values used to deduce mitochondrial HAD+/¥ADH
-9ratios, assuming pH 7*0 and an equilibrium constant of 4*93 x 10 y for 
the 3-hydroxybutyrate dehydrogenase reaction (Williamson et al., 1967)* 
Phenformin invariably caused a decrease in the mitochondrial ’SKD^ /m HE - 
ratio in the liver (1.91 S.E.M. of 0*1, n«4,compared to control, 9*4 '
2*9, n=5f P< 0.05 for fed rats? 7*810.8, n«6,compared to control, 13*91 
3*6, n=5t P < 0.01 for starved rats; 1*710.3, n-7? compared to control, 
4.410.8, n=*4, P^0.01 for diabetic rats). In muscle, however, phen­
formin did not cause any statistically significant changes (88.7 £  21.0; 
n«6jcompared to control 113*1 1 13*7» n*4, for fed rats; 4*610.9, n*6, 
compared to control 3*5£0.8, n=*3, for starved rats; 0.810.3, n»4>com­
pared to control 1*210.4, n=4, for diabetic rats)./-The_reason for the 
high mitochondrial ratios in both control and experimental fed
animals is unclear.
Phenformin did not have consistent effects on blood and tissue 
levels of citrate, glutamate, succinate or malate (Pigs. 4*20 - 4*22). 
Liver citrate and muscle malate were raised in fed rats and muscle citrate
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Pig. 4*22 Liver and muscle succinate and malate concentrations in fed (P)t
starved (S) and streptozotocin-dia'betic jp) -rats- following intraperitoneal 
-administration of phenformin. Legend as for Pigv 4.14. - ;
5 »- LIVER SUCCIMTE (pnol/g) 5 f ITOCLE SUCCIMTE ^ol/g)
T
3-
1-0 p LITER MALATE (jimol/g)
OS
06
0-4 -
0-2
0*5
0*4
0*3
0*2
0*1
- MJSCLE MALATE (jLunol/g)
in diabetic animals but no other differences were statistically signi­
ficant, although there was a tendency for blood glutamate to be elevated . 
in phenformin-treated animals.
The contents of the nicotinamide-adenine dinucleotides in liver and 
muscle were unchanged following administration of phenformin to strep— — 
tozotocin-diabetic rats, and the 1TAD+/HADH and 1TADP+/M.DPH ratios, cal­
culated using individual metabolite concentrations, were also unchanged 
(Table 4.1).
4.3.5 Effects of phenformin on glucose absorption in rat netunal sacs 
In experiments involving the use of everted jejunal sacs phenformin 
did not exert its characteristic hyperlactataemic effect (Table 4*2). 
Although it had small blood glucose-lowering actions in fed and starved 
rats, it also seemed to protect the animals from the hyperlactataemia 
which developed in control animals, so that blood lactate concentrations 
in rats receiving phenformin were lower than those in control animals. 
This effect was most pronounced in starved animals. In fed and starved 
rats phenformin apparently increased mucosal glucose absorption and in 
all three animal models serosal glucose concentrations were lower in sacs 
taken from rats that had received phenformin.
4.4 Discussion
The hypoglycaemic and hyperlactataemic effects of phenformin are 
enhanced in starved rats pretreated with an inhibitor of microsomal 
hydroxylation (Pig. 2.5 ? Holloway-and Alberti, 1976). Conversely, 
pretreatment with an activator of the microsomal mixed function oxidase 
system decreased the hypoglycaemic action of phenformin in starved 
guinea pigs (Cook et al.t 1973a*), suggesting that the biguanide is 
metabolised to a less pharmacologically active form. Phenformin is 
metabolised in rats to 4-hydroxyphenformin and its glucoronide (Beck­
mann, 1968), which together account for more than half the radioacti-
Table 4*1 Liver and muscle nicotinamide-adenine dinucleotide concentrations
in streptozotocin-diabetic rats following administration of phenformin
LIVER
BAD
SADH
DADP
BADPH
SALIBB
385
(±37)
234
(£30)
56
(£5)
66
(£13)
BAD+/DADH 1.7  
(±0.3)
badp+/m d p h  0.9 
(±0.1)
PHEBFORHUT
444
(±24)
163
(±24)
76
(£8)
103
(±25)
3.0
(±0.8)
1.3
(±0.5)
MUSCLE
SALIBB
321
(£14)
131
.(±*5)
12
(£3)
1.3
(±0.9)
PHEHFORMCT
356
(±16)
163
(±27)
8
(±2)
2.4
(±0.7)
Streptozotocin-diabetic rats were given phenformin (0.5nunol/kg i.p.) or 
saline. After 1.8h the animals were anaesthetised with sodium pento­
barbitone and at 2h tissues were sampled. Other details in legend to 
Pig. 4*14* Results as group mean (±S.E.M.)#
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vity eliminated in the 24h urine after a\0*41mmol/kg intraperitoneal 
dose of [2X— phenformin (Guest at al., 1979)• In streptozoto­
cin-diabetic rats 4-hydroxyphe‘nformin, at a dose at which phenformin 
was active, had no effect on blood glucose or lactate concentrations 
(Pigs* 4*1 and 4*2), in agreement with previous findings in fed rats 
(Guest et al.* 1980), rats with chronic renal insufficiency (Heuclin 
et al** 1975)» niice (Beckmann, 19^7) an& guinea pigs (Kuhnle et al*, 
1978)* Although 4-hydroxyphenformin has been reported to be about 
half as effective as phenformin in causing hypoglycaemia in rats 
(Wick et al,, 1970), no details of this study were reported* In 
studies in vitro 4-hydroxyphenformin had no effect on the uptake of 
glucose across hamster intestine rings (Caspary and Creutzfeldt, 1971)* 
or on gluconeogenesis in perfused guinea pig liver and rat liver (Oook 
et al*, 1973a)* Thus the metabolism of phenformin leads to its inac­
tivation, and it may be that poor metabolisers of the drug are more 
prone to the lacticacidosis which occasionally accompanies. therapy 
with phenformin (dates et al*, 1981)•
4-Ethoxyphenformin, a novel compound likely to be metabolised by 
de-ethylation to yield 4-hydroxyphenformin, was pharmacologically 
inactive in streptozotocin-diabetic rats, causing if anything slight 
hyperglycaemia rather than hypoglycaemia (Pig. 4*1)* It does not, 
therefore, appear to warrant further investigation as a potential 
antidiabetic agent*.
4-Fluorophenformin appeared to have no hypoglycaemic activity in 
streptozotocin-diabetic rats (Pig* 4*3), although it is a more potent 
inhibitor of gluconeogenesis in perfused rat liver than is phenformin 
itself (Cook et al*, 1973a). Its marked and long-lasting hyperlactat­
aemic effect (Fig* 4«4) in the absence of any frank antidiabetic 
action implies that the characteristic metabolic effects of biguanides
of hypoglycaemia and hyperlactataemia are not always coupled, although 
a subsidiary action such as an acceleration of muscle glycogenolysis 
would also account for the findings.
Although phenformin caused hypoglycaemia and hyperlactataemia in 
fed, starved and streptozotocin-diabetic rats, it improved tolerance 
to an intraperitoneal glucose load only in fed and starved animals 
(Pigs. 4*5 “ 4*7)« Since all (starved rats) or nearly all (fed rats) 
of the excess lactate could be accounted for by the deficit in glucose, 
it may be that phenformin directly increases the conversion of glucose 
to lactate i.e. it enhances anaerobic glycolysis. The anomaly of marked 
hyperlactataemia in the absence of any frank antidiabetic action of 
phenformin in diabetic rats may be due to the variability of the ini­
tial blood glucose concentrations of these animals, so that phenformin 
may have exerted its blood glucose-lowering effect in rats with parti­
cularly high initial blood glucose concentrations without this anti­
diabetic effect becoming apparent.
Since a glucose load had been given, inhibition of gluconeogen— 
esis by phenformin could not account for the improvement of the toler­
ance to glucose found in fed and, particularly, starved rats. In 
starved animals very little of the glucose load could be measured in 
the blood, implying increased uptake by the tissues, impaired absorp­
tion across the peritoneum or increased excretion by the kidney.
ITeither of the last two effects would allow for increases in blood 
lactate concentration of the magnitude observed, so it seems that 
phenformin leads to increased uptake and glycolytic breakdown of 
glucose by the peripheral tissues. That phenformin was able to im­
prove the handling of glucose by starved rats receiving sodium fluor­
ide, returning the area under the tolerance curve to the control level 
(Pig. 4 «9 )t also suggests that the biguanide is acting to increase the
flux through glycolysis, since fluoride inhibits the glycolytic enzyme 
enolase (Shearer and Suttle, 1970)* Similarly, phenformin caused hyper­
lactataemia even in animals that had received fluoride, again implying 
that increased blood lactate concentration is associated with increased 
glucose disposal to the tissues*
The great improvement caused by phenformin in the intraperitoneal 
glucose tolerance of starved rats is in contrast to previous findings 
with the same animal model in which buformin (W1 -butylbiguanide) im­
proved the tolerance to an oral but not to an intraperitoneal glucose 
load (Lorch, 1971)• Phenformin caused a great improvement in the oral 
glucose tolerance of fasting humans but did not change their intra­
venous glucose tolerance (Hollobaugh et al., 1970) and similar results 
were obtained with starved rats (Gulbenkian et al., 1973), arguing 
against significant peripheral or hepatic actions of phenformin but 
implying an inhibition of the rate of intestinal glucose absorption.
A subcutaneous glucose load, however, caused hyperglycaemia in control, 
partially-eviscerated guinea pigs, but in phenformin-treated animals 
pronounced hypoglycaemia occurred (ifielsen et al., 1958)* Since the 
pancreas had been removed and the hepatic artery tied off this effect 
could not have been due to stimulation of insulin secretion or a reduc­
tion in hepatic glucose output, leaving increased glucose uptake by the 
peripheral tissues as a possible explanation.
The present results for parenteral glucose tolerance tests in fed 
and starved animals indicate increased glucose uptake and lactate pro­
duction by the peripheral tissues, effects found in vitro using isolated 
hemidiaphragms from starved rats but with rather high concentrations 
(0.1 - 2*5mM) of phenformin (Tyberghein and Williams, 1957? Williams 
et, al., 1957? Steiner and Williams, 1958). More recent findings have 
been less equivocal. Phenformin treatment caused increased utilization
of glucose by forearm muscle of maturity-onset diabetics during muscular 
work (Wicklmayr and Mayer, 1977)» indicating that phenformin enhances 
glucose uptake by muscle. During recovery after the work lactate re­
lease from the forearm in these diabetics dropped more slowly after 
phenformin treatment, suggesting increased lactate release due to 
accelerated anaerobic glycolysis. Accelerated conversion of glucose 
to lactate was also found in healthy humans given phenformin (Kreisberg, 
1968). Since glucose oxidation was decreased it was concluded that 
phenformin increased glucose utilization in peripheral tissues by 
increasing the rate of nonoxidative pathways. Similarly, in a study 
of the lactate kinetics of a human diabetic with hyperlactataemia 
caused by phenformin (Searle and Siperstein, 1975)* was concluded 
that phenformin enhanced glucose metabolism to lactate but relatively 
inhibited the production of carbon dioxide from lactate. Although 
lactate oxidation was increased, aerobic metabolism did not keep pace 
with the increased level of anaerobic glycolysis caused by the drug.
The increased gluconeogenesis from lactate also found was considered 
to be a compensatory mechanism that prevents expression of severe 
hyperlactataemia in most diabetics receiving phenformin.
Against this evidence for a peripheral mechanism of action for 
phenformin, however, must be set findings suggesting that the metabolic 
derangement is located in the liver. In hepatectomised rats, phenfor­
min was found to decrease rather than increase peripheral lactate 
release (Holloway, 1978), indicating that hyperlactataemia must be 
due primarily to impaired hepatic uptake of lactate. A decrease in 
lactate uptake was also noted in phenformin-perfused livers taken from 
starved-guinea pigs (Lloyd et al., 1975) and diabetic rats (Cook, 1978). 
Also, no significant change was found after phenformin treatment in the 
rate of glucose removal from the blood of human diabetics (Searle and
Gulli, 1980)» again arguing against a peripheral mechanism of phen­
formin action.
Very few studies have been reported of the effects of admini­
stration of gluconeogenic compounds in vivo on the hypoglycaemic and 
hyperlactataemic actions of phenformin, although the biguanide aboli­
shed the hyperglycaemic effect of an intravenous infusion of sodium 
lactate in fed rats (Assan et al., 1978), as it did in starved rats 
in the present study (Pig. 4.10).
Although all of the gluconeogenic loads did cause increases in 
the blood glucose concentrations of control, starved rats, only fruc­
tose, glycerol, succinate and to a lesser extent malate were able to 
prevent phenformin-induced hypoglycaemia and hyperlactataemia (Pigs.
4*10 and 4*11)* The other compounds — lactate, citrate and 2-oxoglu—
+
tarate - require HAD in the first stage of their energy-yielding 
metabolic conversions to pyruvate, isocitrate and succinylcoenzyme A 
respectively, and one mechanism of biochemical action of phenformin 
that can be postulated from these results, and which is consistent 
with the findings of some previous workers, is that phenformin inhi­
bits HADH dehydrogenase, thus decreasing the mitochondrial HAD+/HADH 
ratio. / The decrease in aerobic respiration that would occur as a 
consequence of this inhibition would lead to an increase in anaerobic 
respiration -<the glycolytic breakdown of glucose to lactate - so that 
the energy demands of the tissues could be met as fully as possible. 
Two of the possible consequences of inhibition of WABH dehydrogenase 
would, therefore, be a decrease in blood glucose concentration and an 
increase in blood lactate concentration, effects characteristic of 
phenformin treatment. Indeed, administration of known inhibitors of 
respiration, such as azide and cyanide, caused hyperglycaemia then 
hypoglycaemia and hyperlactataemia in starved rabbits (Handler, 1945).
Inhibition of BADH dehydrogenase would disrupt the mitochondrial 
electron-transport chain and the formation of ATP by oxidative phos­
phorylation would be decreased, possibly inhibiting gluconeogenesis 
which requires 6 moles of ATP for each mole of glucose produced from 
lactate. Although lowered hepatic ATP levels have been associated 
with inhibition by phenformin of gluconeogenesis from lactate and 
glycerol in vitro (Altschuld and Kruger, 1968), others have found no 
such relationship (Haeckel and Haeckel, 1972) but suggested that a 
decreased ratio raises the concentration of malate with
respect to oxaloacetate, thus decreasing the concentration of oxalo- 
acetate available for conversion to phosphoenol-pyruvate in glucone— 
©genesis. Similarly, decrease of the mitochondrial HAD+/HADH ratio by 
phenformin would lead to inhibition of the metabolism of lactate to 
pyruvate and of citrate, 2-oxoglutarate and malate in the tricarboxylic 
acid cycle. Thus these compounds would not be gluconeogenic in phen­
formin—treated animals and, since they would not allow the production 
of any energy, they would not prevent the acceleration of anaerobic 
glycolysis caused by the biguanide.
In contrast, each mole of succinate would produce 2 moles of ATP 
in its * -flavoprotein-linked conversion to fumarate, the FADE entering 
the respiratoiy. electron-transport chain at the reaction beyond HADH 
dehydrogenase. Succinate would, therefore, reduce the demand for 
energy in animals receiving phenformin and hence the hypoglycaemic 
and hyperlactataemic effects of the drug would be decreased. The block 
of malate due to the low HAD+/lTADH ratio would prevent succinate from 
being converted to oxaloacetate and so succinate would not be glucone­
ogenic in animals given phenformin.
The experimental findings fit the hypothesis well except those 
for malate, where the blood glucose concentration of rats receiving
phenformin did not fall as expected. It may “be that due to its proxi­
mity to oxaloacetate a small amount of gluconeogenesis occurred from 
malate before the decrease in the NAD+/M33H ratio fully inhibited the 
malate dehydrogenase reaction. Malate rapidly enters mitochondria 
from the cytosol, being involved in the transport of reducing equi­
valents between the two compartments. The area tinder the lactate curve 
for malate was more than double that for succinate (see section 4«3*3)» 
suggesting that malate may resemble lactate, 2-oxoglutarate and citrate 
citrate more than it resembles succinate.
Both fructose and glycerol were able to prevent the hypogly­
caemia and hyperlactataemia normally associated with phenformin, pre­
sumably by entering the glycolytic pathway at dihydroxyacetone phos­
phate and producing a net gain of ATP in their conversion to pyruvate. 
Glycerol, gluconeogenic even in animals receiving phenformin, is 
readily converted in the cytosol to o(-glycerophosphate, which is in­
volved in the transport of reducing equivalents across the mitochon­
drial membrane. Mitochondrial ©(-glycerophosphate dehydrogenase is a 
flavoprotein and so even in the presence of phenformin glycerol pro­
vides a gluconeogenic substrate and a supply of energy - ATP produced 
from PADHg in the mitochondrial electron-transport chain - which may 
be adequate to allow gluconeogenesis to occur.
If phenformin causes hypoglycaemia and hyperlactataemia by inhibi­
ting HADH dehydrogenase and thun interfering with the production of ATP 
from the mitochondrial electron-transport chain, substrates which 
provide reducing equivalents that enter the chain at the subsequent 
flavoprotein reaction should be able to prevent and reverse these 
effects. Such substrates are succinate, o(-glycerophosphate and fatty 
acids. Succinate was able to prevent the development of hypoglycaemia 
and hyperlactataemia in starved rats receiving phenformin (Pig. 4«12),
consistent with findings in guinea pig liver mitochondria (Ogata ot 
al.t 1974) in which rates of oxygen uptake and ADP phosphorylation 
were markedly inhibited by phenformin with malate or glutamate as 
substrate but were unchanged with succinate. Similarly, direct 
inhibition by phenformin of the oxidations of pyruvate, citrate, 
2-oxoglutarate and fumarate but not succinate was found in tissue 
homogenates from several species (Ungar et al., 1960). Addition of 
an uncoupling agent such as 2,4-dinitrophenol or of HAD+ itself partly 
overcame the inhibition produced by phenformin, again suggesting in­
hibition of respiration at IJADH dehydrogenase. Although the results 
of another study, using radiolabelled substrates, indicated that phen­
formin inhibited succinate oxidation (Wick et al., 1958), on balance 
phenformin seems to inhibit the oxidation of 1IAD -linked substrates in 
the tricarboxylic acid cycle but not that of succinate.
A fatty acid load, given as glyceryl tripalmitate, had little 
effect on the hypoglycaemic and hyperlactataemic actions of phenformin 
in starved rats (Pig. 4«13), although previous workers (Muntoni et al.,
1978) had shown that glyceryl tristearate reversed these effects. 
Although it was suggested that the free fatty acids were causing 
efflux of the biguanide from the mitochondria, thus restoring res­
piration (Davidoff, 1968b), an alternative explanation could be that 
they were providing a source of energy, via PADH^, in a similar way to 
succinate in the present study. Thus the rate of glycolysis in the 
peripheral tissues of animals receiving phenformin would be decreased 
and the blood glucose and lactate concentrations returned towards 
normal levels. These effects were not clearly obtained in the present 
study, possibly because the time between oral administration of the 
glyceryl tripalmitate and anaesthesia of the animals was not long 
enough to allow substantial absorption of fatty acids from the gut.
Very few reports of the effects of phenformin on the concentra­
tions of tissue metabolites in vivo have been published* The changes 
found in liver and muscle glycogen (Pig. 4*14) generally concur with 
the results of previous workers (see 1.1.2), although the decrease in 
hepatic glycogen in streptozotocin-diabetic rats receiving phenformin 
appears to be a novel finding. Apart from the tendency for a decreased 
mitochondrial HAD+/HADH ratio in liver (see 4*3*4), the results provide 
little support for the hypothesis that phenformin acts to inhibit M D H  
dehydrogenase. Blood or tissue citrate concentrations, for example, 
were not consistently raised, although citric acid was found to accum­
ulate in the blood of animals given compounds structurally-similar to 
biguanides - guanidines and diguanidines (Martenson, 1948).
The action of phenformin in lowering the lactate concentration of 
blood sampled from the inferior vena cava immediately after cervical 
dislocation (ThbTe\ 4*2) maybe due to interference in the development 
of the hypoxic condition which occurs after death and which could be 
responsible for the very high blood lactate concentrations of control 
animals. If phenformin were inhibiting KADH dehydrogenase so that 
tissue ratios were elevated and gluconeogenesis was stimu­
lated in a compensatory mechanism to deal with increased lactate and 
pyruvate concentrations, further changes in the ITAD+/KADH ratio and 
lactate due to hypoxia would be minimal. In control rats, however, 
hypoxia following death would cause a sudden and rapid increase in 
mitochondrial and hence cytosolic HAJD+/M ])H  ratios, and blood lactate 
concentrations would rise sharply.
Administration of phenformin to fed and starved rats in vivo in­
creased the intestinal mucosal absorption of glucose measured in vitro 
(Table 4*2), in contrast to previous findings in starved rats (Kruger 
et al.. 1970? Lorch, 1971) and hamsters (Caspary and Creutzfeldt, 1971)*
Others (Pearson et al.. 1980) found that phenformin was effective when 
placed on the serosal as well as the mucosal surface of rabbit ileum 
and concluded that the action of phenformin was not directly on the - 
sugar carrier site but was due to some metabolic effect within the 
cells, possibly a depletion of the ATP pool. The present results - 
decreases in the glucose concentrations of both serosal and mucosal 
solutions - suggest that phenformin is also active at both surfaces 
of the rat jqjunom but that its action of increasing the uptake of 
glucose, possibly secondary to an acceleration in glycolysis, pre­
dominates over any inhibitory action on glucose absorption.
In contrast, results for blood glucose and lactate concentrations 
in starved, phenformin-treated rats after an oral glucose load (Pig. 
4.8) suggest that little if any of the glucose is absorbed from the 
gut - see 4*3.2. Thus it appears that under conditions existing 
in vivo, with the intestine receiving nutrients and oxygen normally 
in its blood supply, the inhibitory action of phenformin on glucose 
absorption becomes apparent. This inhibition could nonetheless be 
due to a fall in ATP levels following inhibition of the mitochondrial 
electron-transport chain. In conditions existing in vitro. however, 
with no blood supply and a tendency to hypoxia, phenformin exerts its 
more characteristic action of increasing glucose uptake into cells.
CHAPTER 5 
FIUAL DISCUSSION
An animal model of phenformin-induced hyperlactataemia would "be 
of use when assessing the pharmacological and toxicological activities 
of new antidiabetic compounds based on the biguanide structure and in 
determining the efficacy of other compounds, such as dichloroacetate, 
in preventing or reversing the hyperlactataemia. Of the three types 
of animal model - normally-fed, starved and diabetic - the first has 
the advantage that no preliminary treatment of the animal is needed, 
but the relevance of results obtained in animals with a metabolic 
state very different to that of human maturity-onset diabetics may 
be limited, especially since phenformin at usual therapeutic doses 
has little effect on the blood glucose concentration of fed, non­
diabetic humans (Sterne, 1969)* I» fed rats, however, phenformin 
caused marked hypoglycaemia and hyperlactataemia (Guest et al#, 1980) 
at a dose similar to that used to reduce significantly the hypergly- 
caemia of streptozotocin-diabetic rats (Polacek and Ouart, 1974)*
Fed rats thus appear to give an anomalous response to phenformin 
when compared to that shown by -^nondiabetic humans, and most attempts 
to produce a model of hyperlactataemia caused by phenformin have used 
starved animals,- Starved rats, however, are resistant to the pharma­
cological action of phenformin (Altschuld and Kruger, 1968; Muntoni et 
al., 1970? Gulbenkian et al., 1973? Polacek and Ouart, 1974)* In the 
present study phenformin had only marginal effects on the blood glucose 
and lactate concentrations of starved, pentobarbitone - anaesthetised 
rats (Fig. 2.4) unless the phenformin was administered before the 
anaesthetic (Fig. 2.9)* Inhibition of microsomal drug hydroxylation 
allowed phenformin to cause marked hypoglycaemia and hyperlactataemia 
in starved rats (Fig. 2.5; Holloway and Alberti, 1976; Holloway and 
Alberti, 1977) "but such inhibition does not occur to any extent in human 
diabetics (Eaintith ej^  al., 1976)* Others (Assan et al.t 1978; Muntoni
et al., 1978) have used surgically-produced renal failure to increase 
the metabolic effects of phenformin in starved rats.
Starvation produces several metabolic changes similar to those 
found in diabetes (Parrilla, 1978) - an increased rate of glucone— 
ogenesis, depletion of hepatic glycogen stores, mobilization of tri­
glycerides and increased oxidation of fatty acids, together with a 
marked decrease in secretion of insulin. The major difference is that 
diabetics are hyperglycaemic while starved animals have a blood glucose 
concentration that is lower than that of fed animals. Thus a starved 
animal model was considered useful in studies in which the high blood 
glucose concentration of diabetic animals was inappropriate, although 
for phenformin to have effects of a suitable magnitude it had to be 
given before pentobarbitone anaesthetia. Ideally, cannulated rats 
would have been used in all experiments, thus avoiding the use of an 
anaesthetic having its own profound metabolic effects. This was not 
practicable and a comparison of the actions of phenformin in cannul— 
ated and pentobarbitone-anaesthetised animals demonstrated the need 
for caution when drawing conclusions from studies using barbiturate 
anaesthesia.
The streptozotocin-diabetic rat was considered a suitable animal 
model for studies of the antidiabetic and hyperlactataemic actions of 
phenformin since its metabolic state resembles that of human maturity- 
onset diabetics (see 2.4; Kaul et al.« 1978). Phenformin was pharma— 
cologically-active even in pentobarbitone-anaesthetised rats (Pig. 
2.13), as it was in conscious streptozotocin-diabetic animals (Polacek 
and Ouart, 1974? Holloway and Alberti, 1975)* In the present study an 
intravenous dose of streptozotocin of 0.19mmol/kg caused hyperglycaemia 
of a suitable magnitude (blood glucose concentration of 14-20mM) in 
most animals after 24h. Others have used similar doses to produce a
fairly severe diabetic state (Bar-On et al., 1976; Qanda et al.t 1976). 
Although streptozotocin-diabetic rats are often not used for some time 
(1-16 weeks) after injection of the diabetogen, for convenience in the 
present work they were used only 24h later* This may explain the fall 
in blood glucose concentration seen even in control animals in some 
experiments (e.g. Pigs* 4*1 and 4*2) since cyclical fluctuations in 
glycaemia occur in streptozotocin-diabetic rats for at least 78. after 
induction of diabetes (junod et al*, 1967)*
Several halogenated monocarboxylates, including monocholoroacetate, 
trichloroacetate, difluoroacetate, 2-chloropropionate and 3-chloropro- 
pionate, share with dichloroacetate the ability to inhibit pig heart 
pyruvate dehydrogenase kinase (tfhitehouseet al •, 1974)* Most of 
these are also able to activate pyruvate dehydrogenase in rat heart 
mitochondria* As evidence for the potential.toxicity of dichloroace­
tate has accumulated further work with activators of pyruvate dehydro­
genase has concentrated on 2-chloropropionate, which cannot be meta­
bolised to oxalate* It was found that 2-chloropropionate was as effec­
tive an activator of pyruvate dehydrogenase as dichloroacetate in hepa- 
tocytes isolated from starved rats (Crabb and Harris, 1979), and infusion 
into starved rats produced the expected decreases in blood glucose, 
pyruvate and lactate concentrations and increase in blood ketone body 
concentration. Leucine oxidation in hepatocytes from starved rats was 
not affected by 2-chloropropionate, presumably because unlike dichloro­
acetate it cannot be metabolised to glyoxylate which acts as an acceptor 
of amino groups during transamination (Harris et al., 1978)* 1^ perfused
rat heart, however, both 2-chloropropionate and dichloroacetate increase 
leucine oxidation, probably by relieving inhibition by pyruvate of 
2-oxoisocaproate dehydrogenase following their activation of pyruvate 
dehydrogenase (Sans et al., 1980).
Although 2-chloroprbpionate does not have the potential for oxalate 
toxicity associated with dichloroacetate, before it can be used clini­
cally it will have to be subject to strict toxicity testing in the light 
of the severe toxicity recently demonstrated for dichloroacetate in 
animals (Katz et al., 1981) and humans (Moore et al.. 1979)* Similarly, 
although dichloroacetamide prevented hyperlactataemia caused by phen— 
formin in streptozotocin-diabetic rats (Fig. 3.10) the products of its 
metabolism are likely to be the same as those of dichloroacetate, so 
that it may offer no particular advantage over the acid for use in 
therapy of human diabetics. Thus the potential usefulness of activa­
tors of pyruvate dehydrogenase in the treatment of maturity-onset dia­
betes and biguanide-induced hyperlactataemia has yet to be realised.
There is much support, both in the experimental findings presented 
in this thesis and in the literature, for the hypothesis that phenformin 
causes hypoglycaemia and hyperlactataemia by increasing the rate of 
anaerobic glycolysis following inhibition of the mitochondrial electron- 
transport chain at 1TADH dehydrogenase. That phenformin increases the 
peripheral uptake of glucose from the circulation and its glycolytic 
conversion to lactate is indicated by improvements in parenteral 
glucose tolerance (Figs. 4*5 and 4.6) and increased absorption of glu­
cose from both serosal and mucosal surfaces of jejunal sacs (Table 4*2). 
Also, phenformin restored to normal the impaired glucose tolerance of 
rats receiving fluoride, an inhibitor of the glycolytic enzyme enolase 
(Fig. 4.9). Tbe locus of phenformin action being 1TADH dehydrogenase 
was suggested by the finding that succinate but not lactate, citrate 
or 2-oxoglutarate prevented phenformin—induced hypoglycaemia and 
hyperlactataemia in starved rats and that succinate was not glucone­
ogenic in animals receiving phenformin (Figs. 4.10 and 4.11). This 
implied inhibition of M3 -linked substrate oxidations. Succinate and
fatty acids enter the respiratory chain at the flavoprotein reaction 
following the HASH dehydrogenase reaction. Fatty acids prevented the 
hypoglycaemic and hyperlactataemic effects of phenformin (Muntoni et 
al., 1978) and lowered blood lactate concentrations in the present 
study (Fig. 4*13)* Starved rats are somewhat resistant to the hypo­
glycaemic and hyperlactataemic actions of phenformin (Altschuld and 
Kruger, 1968) and are characterised by high circulating levels of free 
fatty acids (Fig. 2.17). Thus in starved , phenformin-treated animals 
fatty acids may be being used to produce energy in the form of ATP 
from the mitochondrial electron-transport chain, so that anaerobic 
glycolysis is not greatly increased.
In starved rats pentobarbitone anaesthesia prevented the hypo­
glycaemic and hyperlactataemic effects of phenformin (Figs. 2.4, 2.10 
and 2.11). Barbiturates are inhibitors of UADH dehydrogenase (Cohen 
and Marshall, 1968; Macdonald and Warm, 1978) and"pentobarbitone itself 
caused hypoglycaemia in starved rats (Fig. 2.10). Thus inhibition by 
pentobarbitone of the actions of phenformin may be due to its occup­
ation of the same receptor sites as the biguanide, explaining why the 
barbiturate is ineffective at blocking the effects of phenformin when 
it is given after the biguanide (Fig. 2.9). Similarly, the use of 
methylene blue as an acceptor of protons from 1TAJDH has been advocated 
for the treatment of lacticacidosis (Dembo et al., 1975). : Its value, 
however, is doubtful (Alberti and_Kattrass, 1977)» as would be expected 
if the block is at KADH dehydrogenase and not further along the res­
piratory chain. Finally, a metabolic block at pyruvate dehydrogenase, 
such as would be caused by a decreased M D +/UADH ratio secondary to 
inhibition of the mitochondrial electron-transport ohain, was suggested 
when an infusion of thiamine pyrophosphate, a cofactor for the pyruvate 
dehydrogenase series of reactions, greatly reduced the hyperlactataemia
caused by phenformin in dogs (Valette et al., 1975)* Such a block 
would also explain the ability of dichloroacetate, an activator of 
pyruvate dehydrogenase, to counteract the hyperlactataemia caused by 
phenformin (Fig. 3*9)*
Mortality in phenformin-induced lacticacidosis is about 5 
(Alberti and ITattrass, 1977)* Treatment is available, however, which 
is often successful if the patient survives long enough for the drug 
to be eliminated. The first phase of therapy is alkalinisation with 
bicarbonate: large amounts are needed since lactic acid - and hence 
H+- production continues in the liver until the extracellular pH is 
raised above 7 (Lloyd et al., 1973), and in severe cases up to 2 mols 
of bicarbonate may be necessary. The alkalinisation may cause sodium 
overloading, and haemodialysis may then be required. Redox agents 
have also been used in attempts to reverse lacticacidosis. For 
example, methylene blue (which can accept a proton from TTADH) is of 
use in the treatment of lacticacidosis caused by ethanol, though it is 
of little value in treating lacticacidosis produced by phenformin 
(Dembo et al., 1975)* Another possible treatment is insulin given 
with glucose. Although recommended by some (Dembo et al., 1975), 
others have found it of no use in reversing experimental lacticacidosis 
induced by phenformin (Alberti and ITattrass, 1977). Although insulin - 
activates pyruvate dehydrogenase, thus enhancing lactate clearance, it 
also stimulates glycolysis and inhibits gluconeogenesis, actions which 
tend to elevate the blood lactate concentration. Dichloroacetate is a 
more specific activator of pyruvate dehydrogenase than is insulin, but 
its use in humans has been curtailed due to its toxicity (Moore e£ al.,
1979) and mutagenicity (Herbert et al., 1980).
The results of the present study indicate that sodium succinate 
might be of value in reversing clinical lacticacidosis. Since it could
be given as an intravenous infusion it would rapidly reach the peri­
pheral tissues and its toxicity is likely to be extremely low, since 
it occurs naturally in the cells. By allowing the production of ATP 
from the mitochondrial respiratory chain it should decrease the rate 
of anaerobic glycolysis that may have been accelerated following 
inhibition of aerobic respiration by phenformin. Although the suc­
cinate would not remove the block at IIADH dehydrogenase it might 
alleviate its effects, so that the blood glucose concentration and 
pH would rise and the blood lactate concentration fall.
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